Dr. Stacy Loeb - Lectures

Lectures in English

Lectures in Spanish

Dr Stacy Loeb gives frequent lectures around the world on prostate cancer and the use of social media in medicine. Lectures are shown on the map and are listed below the map by region.

All

Australia

21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation

Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media

2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media

USANZ New Zealand Section

Tauranga, New Zealand . October 11-13, 2017

Lecture Topic: Localized prostate cancer update, active surveillance, prostate cancer markers, social media

Category: prostate cancer, social media

Astellas Prostate Cancer Meeting

Hobart, Australia. April 8, 2017

Lecture topic: Markers and Prostate Cancer Screening

Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Melbourne, Australia. April 7, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Sydney, Australia. April 5-6, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Adelaide, Australia. April 4, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Brisbane, Australia. April 3, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Macquarie University Markers Symposium

Sidney, Australia. September 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer, Markers

Prostate Cancer World Congress

Cairns, Australia. August 2015

Lecture Topics: Key publications in prostate cancer, Active Surveillance for prostate cancer, Updates to Gleason grading, Social Media and Prostate Cancer.

Category: Prostate Cancer

Prostate Cancer World Congress

Melbourne, Australia. August 2013

Lecture Topics: Practice changing publications in Prostate Cancer, Smarter PSA Screening with Isoforms and Kinetics, Selecting patients for Prostate Biopsy, Selection and monitoring during Active Surveillance

Category: Prostate Cancer

Australian Prostate Cancer Conference

Melbourne, Australia. August 2012

Lecture Topics: Prostate biopsy complications, Overdiagnosis and Overtreatment of Prostate Cancer

Category: Prostate Complications

Brazil

Paulista Congress of Urology

Brazil (Virtual). October 2020

Topic: Prostate Cancer Screening, Markers and Genetic Testing

Category: Prostate Cancer, Genetics

International Continence Society

Rio de Janiero, Brazil. October 2014

Lecture Topic: Social Media in Medicine

Category: Social media

Canada

Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19

Queens University Visiting Professor

Kingston, Ontario – October 18-19, 2018

Lecture Topics: Social Media in Men’s Health (6th Annual Alvaro and Diane Morales Public Lecture in Men’s Health); Active Surveillance for Prostate Cancer.

Category: Men’s Health, Social Media, Prostate Cancer, Active Surveillance

Canadian Urological Association 2017 Meeting

Toronto, Canada- June 24-27, 2017

Lecture topics: Optimizing Active Surveillance for Prostate Cancer, Serum and Urine Markers to Select Patient for Initial and Repeat Prostate Biopsy

Category: Prostate cancer

Issues & Controversies in Urologic Cancer (ICUC) Conference 2017

Mony Tremblant, Canada. January 19-21, 2017

Lecture Topics: Prostate Cancer Markers, Active Surveillance, Prostate Biopsy

Category: Prostate Cancer

The 10th Atlantic Uro Oncology Meeting

Halifax, Canada. November 14, 2015

Lecture Topics: Prostate Cancer Markers and Active Surveillance

Category: Prostate Cancer

Visiting professor at University of Toronto

Toronto, Canada. October 2014

Lecture Topics: Prostate Biopsy, Active Surveillance

Category: Prostate Cancer

Colombia

1ER CURSO BIENAL DE INNOVACÍON UROLÓGICA SOCIEDAD COLOMBIANA DE UROLOGÍA

Barranquilla, Colombia. October 2015

Lecture Topics (all in Spanish): Prostate -specific Antigen and Biomarkers, Prevention and Management of Prostate Biopsy Complications, Active Surveillance

Category: Prostate Cancer

Second Update Course in Urology (Curso de Actualización en Urología)

Barranquilla, Colombia. March 2015

Lecture Topics: Prostate cancer screening, prostate cancer markers, prostate biopsy

Category: Prostate Cancer

Visiting Professor at Fundación Santa Fe de Bogotá Fundación

Barranquilla, Colombia. March 2015

Lecture Topics: Prostate Cancer Screening, Serum and Urine Markers for Prostate Cancer, Contemporary Prostate Biopsy, Active Surveillance, Social Media in Urology

Categories: Prostate Cancer, Social Media

Sociedad Colombiana de Urologia

Cartagena, Colombia. March 2014

Lectures Topics: PSA screening, Risks of Prostate Biopsy, Active Surveillance, Prostate MRI-based Detection, Castration Resistant Prostate Cancer, and Twitter in Urology

Categories: Prostate Cancer, Social Media

Costa Rica

Congreso Centroamericano y del Caribe de Urología y II Highlights of the 2014 American Urological Association Meeting

San Jose, Costa Rica. August 2014

Lectures on: Active surveillance for prostate cancer, Highlights of the AUA meeting on Localized Prostate Cancer

Category: Prostate Cancer

Dominican Republic

Sociedad Dominicana de Urologia

Punta Cana, Dominican Republic. November 2013

Lectures Topics: PSA Screening, Prostate Cancer Markers, and Prostate Biopsy Complications

Category: Prostate Cancer

England

Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19

European Association of Urology 2017 Congress

London, England. 2017

Lecture topic: Social Media

Category: Social Media

Royal Society of Medicine Urology Section Prostate Cancer Conference

London, England. Ocrober 21, 2016

Lecture topic: Active Surveillance- USA Perspective

Category: Prostate Cancer

Germany

Association of Academic European Urologists (AAEU)

Dresden, Germany . December 15-16, 2017

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer

Heinrich Warner Symposium

Hamburgo, Germany. June 23-24, 2017

Lecture Topic: Clinical Use of Markers in Localized Prostate Cancer

Category: Prostate Cancer

European Association of Urology

Munich, Germany. March 11-14, 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer

Surgery in the 3rd Millennium: The Future is Female

Milan, Italy – April 4-5, 2019

Lecture Topics: When not to do surgery: expanding active surveillance for low-risk prostate cancer; Moderation for Retzius-Sparing Robotic Prostatectomy

Category: Prostate Cancer, Active Surveillance, Surgical Technique

Association of Academic European Urologists (AAEU) Meeting

Rome, Italy . November 30, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer

State-of-the-Art Lecture, Association of Academic European Urologists

Roma, Italy .November, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer

iTRUST International Translational Research Uro-Sciences Team

Roma, Italy .September 26-27, 2018

Lecture Topic: Social Media & Cancer Care: Where are we going?

Category: Cancer, Social Media

Global Congress on Prostate Cancer (PROSCA)

Rome, Italy. February 2015

Lecture topic: PSA Screening Yes or No

Category: Prostate Cancer

European Association of Urology Guidelines Office Chairs Meeting

Florence, Italy. October 2014

Lecture Topic: Social Media in Urology

Category: Social Media

International Genitourinary Cancer Symposium (IGUCC 5)

Rome, Italy. April 2013

Lectures Topic: Nature vs Nurture in Prostate Cancer, and Prostate Specific Antigen Velocity

Category: Prostate Cancer

Korea

Annual Meeting of the Korean Urological Association

Seoul, Korea. October 12-15, 2016

León, Mexico, April 2012

Lectures Topic: Prostate Cancer Screening

Category: Prostate Cancer

Netherlands

Active Surveillance for Low Risk Prostate Cancer Conference

Amsterdam, Netherlands. February 2014

Lecture topic: Risk based prediction models for indolent Prostate Cancer

Category: Prostate Cancer

Erasmus University Medical Center

Rotterdam, Netherlands. November 2010

Dr Stacy Loeb presented on “Active Surveillance: Trends in Use, Patient Selection and Monitoring”

Category: prostate cancer

Location: http://www.labroots.com/webcast/id/554

XXVII Congreso Venezolano de Urología, Congreso de Actualización en Urología Oncológica

Lecture topic: Nuevas marcardores en el cáncer de próstata (en español)

Category: prostate cancer

Location: via Skype to Venezuela

Panama

Global Men’s Health Summit

Panama (Virtual). October 2020

Topic: Early Detection, Diagnosis and Risk Stratification of Prostate Cancer

Category: Prostate Cancer

XXXV Congreso Confederación Americana de Urología

Panama. October 2016

Lecture Topics: Prostate Cancer Active Surveillance, SelectMDx and ConfirmMDx Prostate Cancer Markers, Social Media in Urology

Categories: Prostate Cancer, Social Media

Philippines

Philippines Society of Uro-Oncology

Manila, Philippines. September 2014

Russian Ministry of Health, Institute of Urology

Moscow, Russia. March 2014

Lecture topic: PSA Screening Cost-Effectiveness, Prostate Cancer Markers

Category: Prostate Cancer

South Africa

World Congress of Endourology 2016

Capetown, South Africa. November 8-12, 2016
Lecture topic: Social media in urology
Category: Social Media

Spain

Challenges in Laparoscopy and Robotics

Barcelona, Spain – July 3-4, 2019

Lecture Topics: Social Media in Prostate Cancer, Robotic Prostatectomy Moderation

Category: prostate cancer, surgical technique, social media

European Association of Urology 2015

Malibu, CA – November 7, 2019

Lecture Topic: Role of Social Media in Science Information

Category: Social media

Division of General Internal Medicine, NYU

NY, NY – October 8, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

Inspire Seminar Series, Manhattan Veterans Affairs

NY, NY – October 17, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

Prostate Cancer Foundation 2019 Retreat

Carlsbad, CA – October 1-4, 2019

Lecture Topics: Panel at the PCF Women’s Forum on Navigating Confidence; Moderator and Presenter about Online Information and Side Effects at PCF-Us TOO Patient Advocacy Session

Category: Women In Science, Prostate Cancer, Social Media, Survivorship

American Association of Clinical Urologists (AACU)

Washington DC – October 12-14, 2019

Lecture Topic: Online Presence for Urologists, Clinical Urology in 2019 (Panel)

Category: Social Media, Urology

Hackensack University Medical Center Visiting Professor

Hackensack, New Jersey – October 15, 2019

Lecture Topic: Social Media in Medicine

Category: Social Media

Northeastern Section of the American Urological Association

Syracuse, NY – September, 2019

Lecture topics: Reducing prostate cancer overtreatment with active surveillance; Biomarkers- how do we use them

Category: Prostate Cancer, Active Surveillance, Markers

American Urological Association 2019 Annual Meeting

Chicago, IL – May 2-5, 2019

Lecture Topics: Plenary on Top 10 Apps for Wellness, Work and Study; Prostate Cancer Update Course

Category: Apps, Social Media, Prostate Cancer

University of California San Francisco Urology Grand Rounds

San Francisco, CA – January 9, 2019

Lecture Topic: Social Media in Urology

Category: Social Media

Henry Ford Vattikuti Urology Institute Visiting Professor

Detroit, MI – December 11-12, 2018

Lecture topics: Active Surveillance, Social Media

Category: Prostate cancer, active surveillance, social media

American Urological Association 2018 Meeting

San Francisco, CA. May 18-22, 2018

Lecture topic: Optimizing Technique and Selection for Prostate Biopsy, Prostate Cancer Press Conferences, Prostate Cancer Updates Course

Category: Prostate Cancer

LA Live Advanced Robotic & Open Surgery Symposium

Los Angeles, CA. May 16-17, 2018

Lecture topic: Active surveillance for prostate cancer, Live surgery panel

Category: Prostate Cancer

3rd Annual USC L.A. Live Practical Urology Conference

Los Angeles, California . February 1-3, 2018

Lecture Topic:Using markers to improve selection for prostate biopsy, prostate biopsy complications

Category: Prostate Cancer

Society of Women in Urology

Las Vegas, Nevada. January 19-21, 2018

Lecture Topic: Genomic markers for prostate cancer, social media

Category: Prostate Cancer, Social Media

Chairman’s Rounds at Johns Hopkins Hospital

Baltimore, Maryland. November 16, 2017

Lecture Topic: Update on active surveillance and dissemination of knowledge in urology

Category: prostate cancer, social media, dissemination and implementation science (D&I)

Prostate Cancer Foundation 24th Annual Scientific Retreat

Washington, DC . October 4-7, 2017

Lecture Topic: Women in science panel, poster on crowdfunding in prostate cancer

Category: Women in science, Social Media

Grand Rounds at Washington University

St, Louis, Missouri. June 9, 2017

Lecture Topic: Social media in urology

Category: Social media

Grand Rounds at University of Pennsylvania

Philadelphia, Pennsylvania. May 18, 2017

Lecture Topic: Biomarkers in the diagnosis and management of localized prostate cancer

Category: Prostate Cancer

Royal Society of Medicine Winter Meeting

Lake Tahoe (Northstar, California). January 28-30, 2017

Lecture Topics: Urology Highlights of 2016 as Seen Through the Eyes of Twitter, What Has Happened to Screening for Prostate Cancer in the US?

Categories: Social Media, Prostate Cancer

LA Live 2nd University of Southern California Annual Conference: Practical Urology

Los Angeles, California. January 26, 2017

Lecture Topic: Prostate Cancer Markers

Category: Prostate Cancer Markers

Prostate Cancer Foundation 2016 Scientific Retreat

Carlsbad, California. October 26-29, 2016

Lecture topic: Social media in prostate cancer

Category: Social Media

Advanced Robotic Urology and Prostate Cancer Update (Napa, California)Advanced Robotic Urology and Prostate Cancer Update

Napa, California. August 2016

Lecture Topics: Who to Biopsy and Rebiopsy, Tissue-Based Markers for Prostate Cancer Risk Stratification, Biomarker Panel

Category: Prostate Cancer, Biopsy, Markers

Visiting professor at University of Rochester

Rochester, New York. June 8, 2016

Lecture Topic: Markers in Prostate Cancer Screening and Active Surveillance

Category: Prostate Cancer

American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

Chicago, Illinois. June 3-5, 2016

Lecture Topic: Active Surveillance for Prostate Cancer

Category: Prostate Cancer

American Urological Association (AUA) 2016 Annual Meeting

USA. May 2016

Lecture Topics: Dr Loeb gave a plenary presentation on Prostate Cancer Screening and participated on a panel with Drs Scardino, Catalona, and Hamdy. She also presented a late-breaking abstract at the plenary on Testosterone therapy and Prostate Cancer risk. Dr Loeb also gave invited lectures on Prostate Cancer at the International Prostate Forum and on Social Media at the BAUS/BJUI/USANZ plenary. She chaired the AUA press conference on Prostate Cancer and served as faculty for the Prostate Cancer Updates course.

Categories: Prostate Cancer, Men’s Health, Testosterone, Social Media

Visiting Professor at SUNY Downstate

New York. March 23, 2016

Lecture Topics: Prostate Biopsy Indications, Active Surveillance

Category: Prostate Cancer

UNIVERSITY OF SOUTHERN CALIFORNIA INSTITUTE OF UROLOGY 1ST ANNUAL PRACTICAL UROLOGY CONFERENCE

California, USA. February 4-6, 2016

Lecture Topics: Prostate Xancer surgical Masterclass, Biomarkers and Active Surveillance for Prostate Cancer, Social Media in Urology

Category: Prostate Cancer, Social Media

Society of Women in Urology (SWIU)

USA. January 22-23, 2016

Lecture Topic: Serum, Urine and Tissue Markers in Prostate Cancer

Category: Prostate cancer

26th International Prostate Cancer Update (IPCU)

Colorado, USA. January 20-22, 2016

Lecture Topics: When to do prostate biopsy: Role for PSA and novel biomarkers

Category: Prostate cancer

Visiting Professor at the Division of Urology at Albany Medical College

USA. October 2015

Lecture Topics: Markers in Prostate Cancer Screening and Active Surveillance, Social Media in Urology

Categories: Prostate cancer, Social media

Florida Urological Society meeting

Florida, USA. September 2015

Lectures topics: 1) The Dilemma of an Elevated PSA: The Role of New Biomarkers to Determine When to Biopsy, 2) 4K Score, 3) Social Media in Urology

Categories: Prostate Cancer, Social Media

NYC Urological Research Society 2016

New York, Usa. Sptember 2015

Lecture topic: Decipher test in potential candidates for Active Surveillance

Category: Prostate Cancer, Active Surveillance, Markers

FDUS Future Directions in Urology

Colorado, USA. August 2015

Lecture topic: Social Media in Urology

Category: Social Media

West Africa

International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19

NORTH AMERICA

Active

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

“Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277

Untitled

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Untitled

Loeb S.

“Active Surveillance for Prostate Cancer.”

Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148

Loeb S.

” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

“Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub. PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub. PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

We designed a Markov model showing that active surveillance extends life more than watchful waiting, particularly for men with higher risk features, but this is partly offset by decrements in quality of life from delayed treatment. Trade-offs about the intensity of surveillance should be discussed with patients.

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.”

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

“A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub. PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Using nationwide Sweden data, this study showed that by 2014, active surveillance was selected by 91% of very low risk, 74% of low risk and 19% of intermediate risk patients across the country. These rates are the highest yet reported internationally. Dissociating diagnosis from treatment in men with a low risk of progression can decrease the rate of overtreatment.

Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.”

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693

Tosoian JJ, Carter HB, Lepor A, Loeb S.

“Active surveillance for prostate cancer: current evidence and contemporary state of practice.”

Nature Reviews Urology 2016 Mar 8 epub. PMID: 26954332.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26954332

Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke PL, Schaeffer EM.

“Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.”

American Society of Clinical Oncology Educational Book. 2016;35:e235-45. PMID: 27249729

Link: http://www.ncbi.nlm.nih.gov/pubmed/26954332

Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998

Loeb S, Curnyn C, Sedlander E.

“Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.”

European Urology 2016 Jun 6 epub. PMID: 27283215.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27283215

Reviews/Editorials

Loeb S, Carter HB, Schwartz M, Fagerlin A, Braithwaite RS, Lepor H.

“Heterogeneity in active surveillance protocols worldwide.”

Reviews in Urology 2014;16(4):202-3. PMID: 25548550.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274180/

Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P.

“Five-Year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer.”

Eur Urol 2014, June epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24993868

Other Original Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

Other Original Papers

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

“Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer.”

Journal of Urology 2013 epub September 23.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24071481

Key Papers

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Untitled

Loeb S.

“Active Surveillance for Prostate Cancer.”

Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148

Loeb S.

” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

“Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub. PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub. PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.”

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

“A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub. PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.”

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693

Africa

International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19

World Congress of Endourology 2016

Capetown, South Africa. November 8-12, 2016
Lecture topic: Social media in urology
Category: Social Media

ASIA

Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer

21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation

Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media

2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media

USANZ New Zealand Section

Tauranga, New Zealand . October 11-13, 2017

Lecture Topic: Localized prostate cancer update, active surveillance, prostate cancer markers, social media

Category: prostate cancer, social media

Astellas Prostate Cancer Meeting

Hobart, Australia. April 8, 2017

Lecture topic: Markers and Prostate Cancer Screening

Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Melbourne, Australia. April 7, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Australian Prostate Cancer Conference

Melbourne, Australia. August 2012

Lecture Topics: Prostate biopsy complications, Overdiagnosis and Overtreatment of Prostate Cancer

Category: Prostate Complications

Australia

21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation

Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media

2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media

USANZ New Zealand Section

Tauranga, New Zealand . October 11-13, 2017

Lecture Topic: Localized prostate cancer update, active surveillance, prostate cancer markers, social media

Category: prostate cancer, social media

Astellas Prostate Cancer Meeting

Hobart, Australia. April 8, 2017

Lecture topic: Markers and Prostate Cancer Screening

Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Melbourne, Australia. April 7, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Sydney, Australia. April 5-6, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Adelaide, Australia. April 4, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Brisbane, Australia. April 3, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Macquarie University Markers Symposium

Sidney, Australia. September 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer, Markers

Prostate Cancer World Congress

Cairns, Australia. August 2015

Lecture Topics: Key publications in prostate cancer, Active Surveillance for prostate cancer, Updates to Gleason grading, Social Media and Prostate Cancer.

Category: Prostate Cancer

Prostate Cancer World Congress

Melbourne, Australia. August 2013

Category: Prostate Cancer

Australian Prostate Cancer Conference

Melbourne, Australia. August 2012

Lecture Topics: Prostate biopsy complications, Overdiagnosis and Overtreatment of Prostate Cancer

Category: Prostate Complications

Benign Disease

BenignDisease

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology 2021; S0090-4295(21)00266-1. PMID: 33775787.

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/

Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/

Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub. PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/

Key Paper

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November. PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463

Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.

Loeb S, Semins MJ, and Matlaga BR.

“Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.”

Urology, August 2012; 80: 474. PMID: 22857764.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22857764

Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis.

Gupta AD, Loeb S, Stec A, and Wang MH.

“Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis.”

Urology December 2011; 78: 1414-6. PMID: 21676451.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21676451

Prestenting Improves Ureteroscopic Stone-Free Rates.

Rubenstein RA, Zhao LC, Loeb S, Shore DM, and Nadler RB.

“Prestenting Improves Ureteroscopic Stone-Free Rates.”

J Endourol, November 2007; 21: 1277.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18042014

Contemporary Management of Urosepsis: Updated Critical Care Guidelines.

Loeb S, Vardi IY, and Nadler RB.

“Contemporary Management of Urosepsis: Updated Critical Care Guidelines.”

Contemporary Urology, July 2005

Biomarkers

Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer

Wysock JS, Becher E, Persily J, Loeb S, Lepor H.

“Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.”

Urology. 2020 Apr 12:S0090-4295(20)30339-3. PMID: 32294481

Link: https://pubmed.ncbi.nlm.nih.gov/32294481/

Untitled

Fine ND, LaPolla F, Epstein M, Loeb S, Dani H.

” Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.”

BJU International 2019 May epub. PMID:31055874.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31055874

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance. “

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029c

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869

Loeb S, Dani H.

“Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268

Dani H, Loeb S.

“The Role of Prostate Cancer Biomarkers in Undiagnosed Men.”

Current Opinion Urology 2017; 27: 210-216. PMID 28212119

Link: https://www.ncbi.nlm.nih.gov/pubmed/28212119

Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28661898

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489

Lepor A, Catalona WJ, Loeb S.

“The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics North America.”

2016 Feb;43(1):1-6. PMID: 26614024

Link: http://www.ncbi.nlm.nih.gov/pubmed/26614024

Loeb S.

“Does PCA3 Help Identify Clinically Significant Prostate Cancer?”

European Urology, July 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18684556

Reviews/Editorials

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869

Loeb S, Dani H.

“Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268

Dani H, Loeb S.

“The Role of Prostate Cancer Biomarkers in Undiagnosed Men.”

Current Opinion Urology 2017; 27: 210-216. PMID 28212119

Link: https://www.ncbi.nlm.nih.gov/pubmed/28212119

Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28661898

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489

Lepor A, Catalona WJ, Loeb S.

“The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics North America.”

2016 Feb;43(1):1-6. PMID: 26614024

Link: http://www.ncbi.nlm.nih.gov/pubmed/26614024

Loeb S.

“Prostate Cancer: Is PSA Velocity Useful?”

Nature Reviews Urology, June 2009; 6: 305.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19498408

Loeb S and Catalona WJ.

“Cancer Biomarkers: Discovery and Validation.”

Cancer Letters, January 2007

Key Papers

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

“The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer.”

Journal of Urology 2014 Nov 15 epub. PMID:25463993

Link: http://www.ncbi.nlm.nih.gov/pubmed/25463993

Key Papers

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

“Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.”

BJU International. 2012 Feb;109(4):508-13. PMID: 22296334

Link: http://www.ncbi.nlm.nih.gov/pubmed/22296334

Key Papers

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA.

Journal of Urology May 2011; 185: 1650. PMID: 21419439.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21419439

Blog

Urology Care Foundation- A Great Source of Patient Information

I recently returned from a meeting of the Technology and Publications Committee of the Urology Care Foundation. This is the official foundation of the American Urological Association, which provides educational materials and other resources for patients.

One particularly impressive resource that our committee oversees is the patient magazine called Urology Health Extra. Here is a link to the current issue: http://www.urologyhealth.org/patient-magazine/current-issue. It has timely information on urologic conditions reviewed by experts, presented in a reader-friendly format. I highly recommend this as an excellent resource for patients, and suggest that urology offices order free copies of this for their waiting rooms (http://www.urologyhealth.org/educational-materials/magazine-subscription-bulk).

In addition to these printed materials, our committee plans to expand the digital initiatives of the Urology Care Foundation. Stay tuned for much more on Twitter, Facebook, YouTube, Instagram and Pinterest this coming year!

Welcome to Dr. Stacy Loeb’s blog!

Welcome to Dr. Stacy Loeb’s blog! Stay tuned to this section for urology updates, research findings and conference highlights. Check the publications tab for previous research related to:

prostate cancer: PSA Screening, biomarkers, genetics, epidemiology, prostate biopsy, staging, active surveillance, treatment.
other urology topics: surgical technique, uro-oncology, benign disease
social media

Brazil

Paulista Congress of Urology

Brazil (Virtual). October 2020

Topic: Prostate Cancer Screening, Markers and Genetic Testing

Category: Prostate Cancer, Genetics

International Continence Society

Rio de Janiero, Brazil. October 2014

Lecture Topic: Social Media in Medicine

Category: Social media

Canada

Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19

Queens University Visiting Professor

Kingston, Ontario – October 18-19, 2018

Lecture Topics: Social Media in Men’s Health (6th Annual Alvaro and Diane Morales Public Lecture in Men’s Health); Active Surveillance for Prostate Cancer.

Category: Men’s Health, Social Media, Prostate Cancer, Active Surveillance

Canadian Urological Association 2017 Meeting

Toronto, Canada- June 24-27, 2017

Lecture topics: Optimizing Active Surveillance for Prostate Cancer, Serum and Urine Markers to Select Patient for Initial and Repeat Prostate Biopsy

Category: Prostate cancer

Issues & Controversies in Urologic Cancer (ICUC) Conference 2017

Mony Tremblant, Canada. January 19-21, 2017

Lecture Topics: Prostate Cancer Markers, Active Surveillance, Prostate Biopsy

Category: Prostate Cancer

The 10th Atlantic Uro Oncology Meeting

Halifax, Canada. November 14, 2015

Lecture Topics: Prostate Cancer Markers and Active Surveillance

Category: Prostate Cancer

Visiting professor at University of Toronto

Toronto, Canada. October 2014

Lecture Topics: Prostate Biopsy, Active Surveillance

Category: Prostate Cancer

Colombia

1ER CURSO BIENAL DE INNOVACÍON UROLÓGICA SOCIEDAD COLOMBIANA DE UROLOGÍA

Barranquilla, Colombia. October 2015

Lecture Topics (all in Spanish): Prostate -specific Antigen and Biomarkers, Prevention and Management of Prostate Biopsy Complications, Active Surveillance

Category: Prostate Cancer

Second Update Course in Urology (Curso de Actualización en Urología)

Barranquilla, Colombia. March 2015

Lecture Topics: Prostate cancer screening, prostate cancer markers, prostate biopsy

Category: Prostate Cancer

Visiting Professor at Fundación Santa Fe de Bogotá Fundación

Barranquilla, Colombia. March 2015

Lecture Topics: Prostate Cancer Screening, Serum and Urine Markers for Prostate Cancer, Contemporary Prostate Biopsy, Active Surveillance, Social Media in Urology

Categories: Prostate Cancer, Social Media

Sociedad Colombiana de Urologia

Cartagena, Colombia. March 2014

Lectures Topics: PSA screening, Risks of Prostate Biopsy, Active Surveillance, Prostate MRI-based Detection, Castration Resistant Prostate Cancer, and Twitter in Urology

Categories: Prostate Cancer, Social Media

Colorado - USA

Conference Highlights

ConferenceHighlights

Nickel JC, Gorin MA, Alan W P, Loeb S, Ellen S, Chancellor MB, Assimos DG, Brawer MK, Brucker BM.

“Best of the 2016 AUA Annual Meeting: Highlights From the 2016 American Urological Association Annual Meeting, May 6-10, 2016, San Diego, CA.”

Reviews in Urology 2016;18(3):159-173. PMID: 27833468.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27833468

Nickel JC, Gorin MA, Partin AW, Assimos D, Brawer M, Nicolai H, Chancellor MB, Goggins Á, Loeb S, Shapiro E.

“Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.”

Reviews in Urology 2015;17(3):179-89. PMID: 26543434

Link: http://www.ncbi.nlm.nih.gov/pubmed/26543434

Prostate Cancer Screening Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014.

Loeb S.

“Prostate Cancer Screening Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014.”

Reviews in Urology 2014; 16: 90. PMID: 25009450.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080855/

Advances in Localized Prostate Cancer: Highlights From the 2012 Friends of Israel Urological Symposium, July 3-5, 2012, Tel Aviv, Israel.

Loeb S, Borin JF.

“Advances in Localized Prostate Cancer: Highlights From the 2012 Friends of Israel Urological Symposium, July 3-5, 2012, Tel Aviv, Israel.”

Reviews in Urology 2013; 15: 82.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784972/

Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA.

Loeb S, Assimos D, Chancellor MB, Nickel JC, Brawer MK, Kern AJ, Partin AW.

“Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA..”

Reviews in Urology 2013; 15: 72.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784971/

Best of 2012 AUA Annual Meeting: Highlights from the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.

Nickel JC, Partin AW, Nirmal J, Chancellor MB, Loeb S, Brawer MK, Assimos D, and Shapiro E.

“Best of 2012 AUA Annual Meeting: Highlights from the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.”

Reviews in Urology 2012; 14: 90-103. PMID: 23526762

Link: http://www.ncbi.nlm.nih.gov/pubmed/23526762

Prostate Cancer Screening and Surgical Management of Localized Disease: Highlights from the 27th Annual Congress of the European Association of Urology, February 24-28, 2012, Paris, France.

Loeb S.

“Prostate Cancer Screening and Surgical Management of Localized Disease: Highlights from the 27^th Annual Congress of the European Association of Urology, February 24-28, 2012, Paris, France.”

Reviews in Urology 2012; 14: 87-9. PMID: 23526727

Link: http://www.ncbi.nlm.nih.gov/pubmed/23526727

Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.

Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A.

“Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.”

BJU International 2012; 109 Suppl 2: 1-7. PMID: 22257098.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22257098

Best of the AUA Annual Meeting: Highlights from the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.

Brawer MK, Loeb S, Partin AW, Nirmal J, Chancellor MB, Nickel JC, Rajfer J, Shapiro E, and Roehrborn CG.

“Best of the AUA Annual Meeting: Highlights from the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.”

Reviews in Urology 2011; 13: 151-72. PMID: 22114546.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725309/

Innovation in Endourology and Minimally Invasive Surgery. Highlights from the 29th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan.

Loeb S and Borin JF.

“Innovation in Endourology and Minimally Invasive Surgery. Highlights from the 29^th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan.”

Reviews in Urology 2012; 14: 28-30. PMID: 23172997.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502049/

Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.

Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, and Shapiro E.

“Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.”

Reviews in Urology, Spring 2009; 11: 82.

Costa Rica

Congreso Centroamericano y del Caribe de Urología y II Highlights of the 2014 American Urological Association Meeting

San Jose, Costa Rica. August 2014

Lectures on: Active surveillance for prostate cancer, Highlights of the AUA meeting on Localized Prostate Cancer

Category: Prostate Cancer

Covid19

Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study

Dubin JM, Wyant WA, Balaji NC, Ong WL, Kettache RH, Haffaf M, Zouari S, Santillan D, Autrán Gómez AM, Sadeghi-Nejad H, Loeb S, Borin JF, Gomez Rivas J, Grummet J, Ramasamy R, Teoh JYC.

“Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study.”

J Med Internet Res. 2020 Nov 5;22(11):e21875. PMID: 33031047.

Link: https://pubmed.ncbi.nlm.nih.gov/33031047/

The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R, O’Brien T, Odisho AY, Powles T, Skolarus TA, Smith AB, Szabados B, Klaassen Z, Spratt DE.

“The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.”

Eur Urol. 2020 Nov;78(5):731-742. PMID: 32893062.

Link: https://pubmed.ncbi.nlm.nih.gov/32893062/

Urologic Services in Public Hospitals Suffered a Greater Detriment Than Private Hospitals During the Battle of COVID-19

Ong WLK, Lechmiannandan S, Loeb S, Teoh JY.

“Urologic Services in Public Hospitals Suffered a Greater Detriment Than Private Hospitals During the Battle of COVID-19.”

Urology. 2020 Oct; 144:269-270. Epub 2020 Jul 18.PMID: 32687841.

Link: https://pubmed.ncbi.nlm.nih.gov/32687841/

Telemedicine and Smart Working: Recommendations of the European Association of Urology

Rodriguez Socarrás M, Loeb S, Teoh JY, Ribal MJ, Bloemberg J, Catto J, N’Dow J, Van Poppel H, Gómez Rivas J.

“Telemedicine and Smart Working: Recommendations of the European Association of Urology”

Eur Urol. 2020 Dec;78(6):812-819. PMID: 32654801.

Link: https://pubmed.ncbi.nlm.nih.gov/32654801/

A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic

Heldwein FL, Loeb S, Wroclawski ML, Sridhar AN, Carneiro A, Lima FS, Teoh JY.

“A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic.”

Eur Urol Focus. 2020 Jun 5 epub. PMID: 32532703.

Link: https://pubmed.ncbi.nlm.nih.gov/32532703/

A Global Survey on the Impact of COVID-19 on Urological Services

Teoh JY, Ong WLK, Gonzalez-Padilla D, Castellani D, Dubin JM, Esperto F, Campi R, Gudaru K, Talwar R, Okhunov Z, Ng CF, Jain N, Gauhar V, Wong MC, Wroclawski ML, Tanidir Y, Rivas JG, Tiong HY, Loeb S; UroSoMe Working Group.

“A Global Survey on the Impact of COVID-19 on Urological Services.”

Eur Urol. 2020 May 26 epub. PMID: 32507625.

Link: https://pubmed.ncbi.nlm.nih.gov/32507625/

Dominican Republic

Sociedad Dominicana de Urologia

Punta Cana, Dominican Republic. November 2013

Lectures Topics: PSA Screening, Prostate Cancer Markers, and Prostate Biopsy Complications

Category: Prostate Cancer

Drugsafety

Key Papers

drug safety

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

“Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.”
European Urology. 2015 Dec 29 epub. PMID: 26743040

Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040

A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

Other Papers

Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P.

“Opiod. Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden”

J Urol. 2019 Jul 17 epub. PMID:31584849

Link: https://www.ncbi.nlm.nih.gov/pubmed/31584849

Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P.

“Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.”

J Natl Cancer Inst. 2017 Aug 1;109(8). PMID: 29117385

Link: https://www.ncbi.nlm.nih.gov/pubmed/29117385

Loeb S, Stattin P.

“Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma.”

European Urology 2016 Jul 16 epub. PMID: 27436160.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27436160

Loeb S, Lambe M, Stattin P.

“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

Loeb S, Lambe M, Stattin P.
“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Loeb S.

“Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.”

Urology August 2011; 78: 255. PMID: 21820566.

England

Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19

European Association of Urology 2017 Congress

London, England. 2017

Lecture topic: Social Media

Category: Social Media

Royal Society of Medicine Urology Section Prostate Cancer Conference

London, England. Ocrober 21, 2016

Lecture topic: Active Surveillance- USA Perspective

Category: Prostate Cancer

Epidemiology

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

This study examined effect modification by environmental factors of the association between single nucleotide polymorphisms with prostate cancer risk. Among men at high risk for prostate cancer based on their genotype, use of selenium was associated with a lower risk of advanced prostate cancer, while aspirin, ibuprofen and vegetables were associated with lower risk of nonadvanced prostate cancer.

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

Reviews/Editorials

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159990

Mullins JK, Loeb S.

“Environmental exposures and prostate cancer.”

Urologic Oncology: Seminars and Investigations, March 2012; 30: 216. PMID: 22385992.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22385992

REVIEWS/EDITORIALS

Mullins JK and Loeb S.

“Diabetes Mellitus and Prostate Cancer Risk.”

Expert Review of Endocrinology and Metabolism November 2010; 5: 787.

Reviews/Editorials

Loeb S and Partin AW.

“Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention.”

Reviews in Urology, Spring 2009; 11: 114.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725311/

Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

Primary Care Clinics of North America, September 2009; 36: 603.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19616157

Epidemiology

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

Reviews/Editorials

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159990

Mullins JK, Loeb S.

“Environmental exposures and prostate cancer.”

Urologic Oncology: Seminars and Investigations, March 2012; 30: 216. PMID: 22385992.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22385992

REVIEWS/EDITORIALS

Mullins JK and Loeb S.

“Diabetes Mellitus and Prostate Cancer Risk.”

Expert Review of Endocrinology and Metabolism November 2010; 5: 787.

Reviews/Editorials

Loeb S and Partin AW.

“Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention.”

Reviews in Urology, Spring 2009; 11: 114.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725311/

Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

WALL STREET JOURNAL ARTICLE ON PROSTATE CANCER TESTS

Genetics

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/

Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Loeb S. and Giri VN.

“Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.”

Eur Urol Oncol. 2021 Feb;4(1):1-9. Epub 2020 Dec 31. PMID: 33390340

Link: https://pubmed.ncbi.nlm.nih.gov/33390340/

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O’Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

The 2019 Philadelphia Prostate Cancer Consensus Conference was a multidisciplinary conference including experts and other stakeholders to create a series of recommendations surrounding germline genetic evaluation for prostate cancer.

Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.

Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.

“Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.”

Cancer Treat Res Commun. 2020 Sep 28;25:100212. PMID: 33091732

Link: https://pubmed.ncbi.nlm.nih.gov/33091732/

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379

Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

“Screening for Familial and Hereditary Prostate Cancer“.

International Journal of Cancer.

2015 Dec 5 epub. PMID: 26638190

Link: http://www.ncbi.nlm.nih.gov/pubmed/26638190

Reviews/Editorials

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379

Key Papers

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.

“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/

Correcting the PSA level for a man’s genotype could potentially reduce the number of men referred for prostate biopsy by up to 20%, while reducing the number of potentially delayed diagnoses by 3% for men with genetically lower PSA levels.

Key Papers

Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.”

Cancer Causes Control 2012; December epub. PMID: 23266834.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

First-generation immigrants to Sweden (a high risk country for prostate cancer) have a lower risk of all stages of prostate cancer compared to native-born men, especially men who immigrated to Sweden recently or at an older age.

Reviews/Editorials

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/

Reviews/Editorials

Loeb S.

“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622

Loeb S.
“Germline Sequence Variants and Prostate Specific Antigen Interpretation.”

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622

Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897

Key Papers

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

Reviews/Editorials

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739

Genetics

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/

Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Loeb S. and Giri VN.

“Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.”

Eur Urol Oncol. 2021 Feb;4(1):1-9. Epub 2020 Dec 31. PMID: 33390340

Link: https://pubmed.ncbi.nlm.nih.gov/33390340/

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.

Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.

“Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.”

Cancer Treat Res Commun. 2020 Sep 28;25:100212. PMID: 33091732

Link: https://pubmed.ncbi.nlm.nih.gov/33091732/

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379

Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622

Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897

Key Papers

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

Reviews/Editorials

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739

Germany

Association of Academic European Urologists (AAEU)

Dresden, Germany . December 15-16, 2017

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer

Heinrich Warner Symposium

Hamburgo, Germany. June 23-24, 2017

Lecture Topic: Clinical Use of Markers in Localized Prostate Cancer

Category: Prostate Cancer

European Association of Urology

Munich, Germany. March 11-14, 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer

Heinrich Warner Symposium

Hamburg, Germany. January 2015

Lecture Topics : Genomic and Epigenetic Variations in Prostate Cancer

Category: Prostate Cancer

Grants Completed

Grants Current

Hong Kong

Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer

Hungary

International Genitourinary Cancer Symposium (IGUCC 3)

Budapest, Hungary. March 2011

Lecture Topics: Debate on Active Surveillance, Panel on Controversies in Prostate Cancer

Category: Prostate Cancer

Ireland

John Fitzpatrick Irish Prostate Cancer Conference

Ireland. April 21-22, 2016

Surgery in the 3rd Millennium: The Future is Female

Milan, Italy – April 4-5, 2019

Lecture Topics: When not to do surgery: expanding active surveillance for low-risk prostate cancer; Moderation for Retzius-Sparing Robotic Prostatectomy

Category: Prostate Cancer, Active Surveillance, Surgical Technique

Association of Academic European Urologists (AAEU) Meeting

Rome, Italy . November 30, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer

State-of-the-Art Lecture, Association of Academic European Urologists

Roma, Italy .November, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer

iTRUST International Translational Research Uro-Sciences Team

Roma, Italy .September 26-27, 2018

Lecture Topic: Social Media & Cancer Care: Where are we going?

Category: Cancer, Social Media

Global Congress on Prostate Cancer (PROSCA)

Rome, Italy. February 2015

Lecture topic: PSA Screening Yes or No

Category: Prostate Cancer

European Association of Urology Guidelines Office Chairs Meeting

Florence, Italy. October 2014

Lecture Topic: Social Media in Urology

Category: Social Media

International Genitourinary Cancer Symposium (IGUCC 5)

Rome, Italy. April 2013

Lectures Topic: Nature vs Nurture in Prostate Cancer, and Prostate Specific Antigen Velocity

Category: Prostate Cancer

Key Article

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?”

Journal of Clinical Oncology January 2011; 29: 464.
Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Although number needed to screen (NNS) and number needed to treat (NNT) are useful statistics to assess the benefits and harms of an intervention, in a survival study setting such as the European Randomized Study of Screening for Prostate Cancer (ERSPC), NNS and NNT are time specific, and reporting values at one time point may lead to misinterpretation of results. We developed a model predicting that the NNS in this trial would decrease from 837 at year 10 to 503 at year 12, and NNT would decrease from 29 to 18.

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?”

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

Men ages 75-80 with PSA levels <3 ng/ml are unlikely to die of or experience aggressive prostate cancer during their remaining life, suggesting that PSA testing might be safely discontinued for these men.

Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

This study reviews the published literature showing that baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Baseline PSA testing should be offered to young men for risk stratification and to guide screening protocols

Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

In the general US population, the median PSA level is 0.7 ng/ml in the 40’s and 0.9 ng/ml in the 50’s. Young men with a baseline PSA level above the age-specific median are at significantly greater risk of future prostate cancer diagnosis and aggressive disease. Baseline PSA at a young age is a stronger predictor of prostate cancer than race, family history or digital rectal examination.

Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

In light of numerous conflicting recommendations about prostate cancer screening, in August 2013 a multidisciplinary group convened in Melbourne, Australia to create consensus practice guidelines. Key areas of consensus are that level 1 evidence shows that prostate cancer screening saves lives among men ages 50-69, but that biopsy decisions should be made using PSA as part of a multivariable approach and that diagnosis must be uncoupled from treatment.

Key Papers

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

Untitled

Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A.

“Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.

European Urology. 2018 Nov 27 epub. PMID: 30502104.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30502104

In this study, we examined the first 150 YouTube videos about prostate cancer, showing that the majority had potentially biased and/or misinformative information in the video or comments.

Loeb S, Byrne N, Makarov DV, Lepor H, Walter D.

“Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015.”

JAMA. 2018 Jun 5; 319(21):2231-2233. PMID: 29800017

Link: https://www.ncbi.nlm.nih.gov/pubmed/29800017

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub. PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, Stroup SP.

“An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy.”

Journal of Urology 2017 Mar 29 epub. PMID: 28363690

Link: https://www.ncbi.nlm.nih.gov/pubmed/28363690

This is an updated American Urological Association White Paper with guidance on the prevention and treatment of prostate biopsy complications.

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

Key Papers

Loeb S, Roupret M, Van Oort I, N’dow J, Van Gurp M, Bloemberg J, Darraugh JA, Ribal M.

“Novel Use of Twitter to Disseminate and Evaluate Adherence with Clinical Guidelines by the European Association of Urology”.

BJU Int. 2017 Feb 7 epub. PMID: 28170154

Link: https://www.ncbi.nlm.nih.gov/pubmed/28170154

Herein, we demonstrate a proof-of-principal study on the use of twitter as a platform for the dissemination and real-time evaluation of the European Association of Urology clinical guidelines. These strategies can be considered by other medical societies to increase the reach and obtain rapid feedback on guidelines recommendations.

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.” BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.” European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871

Loeb S, Curnyn C, Sedlander E.

“Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.”

European Urology 2016 Jun 6 epub. PMID: 27283215.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

This is the first qualitative study to ask patients their perspectives on Gleason grading, which is a significant source of confusion. The majority of patients agreed that they would prefer to be told they have grade group 1 versus Gleason 6 cancer, and that this would encourage the use of active surveillance.

Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.”

Cancer Causes Control 2012;

December epub. PMID: 23266834.
Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.
“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.
Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/

Key Articles

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

“Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.”

European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014

Key Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

This systematic review of epidemiological, clinical and autopsy studies found a very wide of estimates for prostate cancer overdiagnosis from 1.7-67%. Published estimates of overtreatment vary widely based on patient features and may be declining internationally. Careful patient selection for screening and reducing overtreatment are important to preserve the benefits and reduce the downstream harms of prostate-specific antigen testing.

Key Papers

Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, and Lotan Y.

“Systematic Review of Complications of Prostate Biopsy.”

European Urology 2013; June epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23787356

This systematic review of prostate biopsy complications found that hematuria and hematospermia are most common, but are typically mild and self-limiting. Severe rectal bleeding is uncommon. Despite antimicrobial prophylaxis, infectious complications are increasing over time and are the most common reason for hospitalization after biopsy. Pain may occur at several stages of prostate biopsy and can be mitigated by anesthetic agents and anxiety-reduction techniques. Up to 25% of men have transient LUTS after biopsy, and <2% have frank urinary retention, with slightly higher rates reported after transperineal template biopsy. Biopsy-related mortality is rare.

Key Papers

Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P.

“Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging.”

Journal of the National Cancer Institute (JNCI) 2013 July epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23853055

Imaging is very important for staging of high-risk prostate cancer, but is not recommended for low-risk disease. This study demonstrated that a nationwide Swedish campaign successfully reduced inappropriate imaging for low risk prostate cancer (from 45% to 3%), but also was associated with a slight reduction in appropriate imaging in high-risk patients.

Key Papers

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

“The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer.”

Journal of Urology 2014 Nov 15 epub. PMID:25463993

Link: http://www.ncbi.nlm.nih.gov/pubmed/25463993

Key Papers

Murphy DG, Loeb S, Basto MY, Challacombe B, Trinh QD, Leveridge M, Morgan T, Dasgupta P, Bultitude M.

“Engaging Responsibly with Social Media: the BJUI Guidelines.”

BJU International 2014 Apr epub. PMID: 24774415

Link: http://www.ncbi.nlm.nih.gov/pubmed/24774415

This paper summarizes the British Journal of Urology International guidelines for physicians to engage responsibly with social media. They emphasize the importance of considering that online content may exist forever and be available to everyone, that doctors should identify themselves and that the views they express are their own. Digital behavior should align with professional standards, avoiding any impropriety or breach of patient privacy.

drug safety

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

“Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.”
European Urology. 2015 Dec 29 epub. PMID: 26743040

Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040

A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

Other Papers

Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P.

“Opiod. Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden”

J Urol. 2019 Jul 17 epub. PMID:31584849

Link: https://www.ncbi.nlm.nih.gov/pubmed/31584849

Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P.

“Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.”

J Natl Cancer Inst. 2017 Aug 1;109(8). PMID: 29117385

Link: https://www.ncbi.nlm.nih.gov/pubmed/29117385

Loeb S, Stattin P.

“Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma.”

European Urology 2016 Jul 16 epub. PMID: 27436160.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27436160

Loeb S, Lambe M, Stattin P.

“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

Loeb S, Lambe M, Stattin P.
“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Loeb S.

“Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.”

Urology August 2011; 78: 255. PMID: 21820566.

Among men undergoing prostate biopsy in the European Randomized Study of Screening for Prostate Cancer (ERSPC), 4% developed a fever and 0.8% were admitted to the hospital. Although the risk of hospitalization for infection increased over time, the absolute frequency was low. Because this same trial showed that screening reduces advanced disease and prostate cancer death, the risk of biopsy-related complications should not dissuade healthy men with a sufficient life expectancy to benefit from early detection from undergoing an indicated prostate biopsy.

Key Papers

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

“Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.”

BJU International. 2012 Feb;109(4):508-13. PMID: 22296334

Link: http://www.ncbi.nlm.nih.gov/pubmed/22296334

Key Papers

Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

Key Papers

Loeb S, Carter HB, Berndt SI, Ricker W, and Schaeffer EM.

“Complications After Prostate Biopsy: Data From SEER-Medicare.”

Journal of Urology November 2011; 186: 1830. PMID: 21926375.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21944136

This was the first paper to call attention to the increasing risk of hospitalization for infection after prostate biopsy in the United States. Careful patient selection for prostate biopsy is essential to minimize the potential downstream harms of prostate cancer screening, and this paper has been cited by numerous guidelines

Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC.

“What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?”

Urology 2009, Nov 19 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19931898

Historically most men with D’Amico high-risk prostate cancer (clinical stage ≥T2c, biopsy Gleason score 8-10, or prostate-specific antigen >20 ng/mL) were treated with combined radiation therapy and hormonal therapy. This study shows that surgical treatment for carefully selected high risk patients can result in long-term progression–free survival. At 10 years, biochemical recurrence-free survival was 68%, metastasis-free survival was 84%, and prostate cancer-specific survival was 92%. The 10-year rate of freedom from any hormonal therapy was 71%. Of the 3 high-risk criteria, a biopsy Gleason score of 8-10 (vs ≤7) was the strongest independent predictor of biochemical recurrence, metastases, and prostate cancer death.

Key Papers

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

Key Papers

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?”

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

Key Papers

Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

Korea

Annual Meeting of the Korean Urological Association

Seoul, Korea. October 12-15, 2016

Sexual Medicine Society of North America Journal Club

USA (Virtual). March 2021

Topic: Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Category: Social Media

NYU Department of Population Health

NYC (Virtual). March 2021

Topic: Social Media Best Practices Workshop

Category: Social Media

ASCO Genitourinary Symposium

USA (Virtual). February 2021

Topic: Moderator

Category: Prostate Cancer

Grand Rounds, Weill Cornell University Urology

NYC (Virtual). January 2021

Topic: Promise and Peril of Digital Technology in Urology

Category: Social Media

Society of Urologic Oncology Young Urologic Oncologists Lecture Series

USA (Virtual). November 2020

Topic: Use of Social Media in Urology

Category: Social Media

21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation

Sexual Medicine Society of North America

USA (Virtual). October 2020

Topic: Social Media in Sexual Medicine

Category: Men’s Health, Social Media

Memorial Sloan Kettering Cancer Center

NYC (Virtual). October 2020

Topic: Social Media in Prostate Cancer

Category: Prostate Cancer, Social Media

Texas A&M University College of Medicine Health & Wellness Grand Rounds

Texas (Virtual). October 2020

Topic: Online Professionalism and the Pros/Cons of Social Media for Medical Trainees and Health Professionals

Category: Social Media

Weill Cornell University Urology

NYC (Virtual). August 2020

Topic: Prostate Cancer Screening

Category: Prostate Cancer

Association for Healthcare Social Media

Pennsylvania (Virtual). August 2020

Topic: Researching Social Media

Category: Social Media

Texas A&M Baylor, Scott & White Health Graduate Medical Education

Texas (Virtual). May 2020

Topic: Social Media

Category: Social Media

EMPIRE Lecture Series

NY (Virtual). May 2020

Topic: Social Media for Urologists

Category: Social Media

Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19

Memorial Sloan Kettering Cancer Center

New York, NY – December 17, 2019

Lecture topic: Social Media and Academics

Category: Social media

Culture Leap

Malibu, CA – November 7, 2019

Lecture Topic: Role of Social Media in Science Information

Category: Social media

Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media

Division of General Internal Medicine, NYU

NY, NY – October 8, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

Inspire Seminar Series, Manhattan Veterans Affairs

NY, NY – October 17, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

Prostate Cancer Foundation 2019 Retreat

Carlsbad, CA – October 1-4, 2019

Lecture Topics: Panel at the PCF Women’s Forum on Navigating Confidence; Moderator and Presenter about Online Information and Side Effects at PCF-Us TOO Patient Advocacy Session

Category: Women In Science, Prostate Cancer, Social Media, Survivorship

American Association of Clinical Urologists (AACU)

Washington DC – October 12-14, 2019

Lecture Topic: Online Presence for Urologists, Clinical Urology in 2019 (Panel)

Category: Social Media, Urology

Hackensack University Medical Center Visiting Professor

Hackensack, New Jersey – October 15, 2019

Lecture Topic: Social Media in Medicine

Category: Social Media

Northeastern Section of the American Urological Association

Syracuse, NY – September, 2019

Lecture topics: Reducing prostate cancer overtreatment with active surveillance; Biomarkers- how do we use them

Category: Prostate Cancer, Active Surveillance, Markers

American Urological Association 2019 Annual Meeting

Chicago, IL – May 2-5, 2019

Lecture Topics: Plenary on Top 10 Apps for Wellness, Work and Study; Prostate Cancer Update Course

Category: Apps, Social Media, Prostate Cancer

Surgery in the 3rd Millennium: The Future is Female

Milan, Italy – April 4-5, 2019

Lecture Topics: When not to do surgery: expanding active surveillance for low-risk prostate cancer; Moderation for Retzius-Sparing Robotic Prostatectomy

Category: Prostate Cancer, Active Surveillance, Surgical Technique

Hot Topics in Uro-Oncology

Zurich, Switzerland – January 25, 2019

Lecture Topic: Prostate Cancer Screening in the Era of MRI and Novel Biomarkers

Category: Prostate Cancer, MRI, Screening, Markers

University of California San Francisco Urology Grand Rounds

San Francisco, CA – January 9, 2019

Lecture Topic: Social Media in Urology

Category: Social Media

Henry Ford Vattikuti Urology Institute Visiting Professor

Detroit, MI – December 11-12, 2018

Lecture topics: Active Surveillance, Social Media

Category: Prostate cancer, active surveillance, social media

Association of Academic European Urologists (AAEU) Meeting

Rome, Italy . November 30, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer

State-of-the-Art Lecture, Association of Academic European Urologists

Roma, Italy .November, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer

iTRUST International Translational Research Uro-Sciences Team

Roma, Italy .September 26-27, 2018

Lecture Topic: Social Media & Cancer Care: Where are we going?

Category: Cancer, Social Media

2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media

American Urological Association 2018 Meeting

San Francisco, CA. May 18-22, 2018

Lecture topic: Optimizing Technique and Selection for Prostate Biopsy, Prostate Cancer Press Conferences, Prostate Cancer Updates Course

Category: Prostate Cancer

LA Live Advanced Robotic & Open Surgery Symposium

Los Angeles, CA. May 16-17, 2018

Lecture topic: Active surveillance for prostate cancer, Live surgery panel

Category: Prostate Cancer

Surgery in the 3rd Millenium: The Future is Female

Milan, Italy . April 12-13, 2018

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer

Association of Academic European Urologists (AAEU)

Dresden, Germany . December 15-16, 2017

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer

3rd Annual USC L.A. Live Practical Urology Conference

Los Angeles, California . February 1-3, 2018

Lecture Topic:Using markers to improve selection for prostate biopsy, prostate biopsy complications

Category: Prostate Cancer

Society of Women in Urology

Las Vegas, Nevada. January 19-21, 2018

Lecture Topic: Genomic markers for prostate cancer, social media

Category: Prostate Cancer, Social Media

Chairman’s Rounds at Johns Hopkins Hospital

Baltimore, Maryland. November 16, 2017

Lecture Topic: Update on active surveillance and dissemination of knowledge in urology

Category: prostate cancer, social media, dissemination and implementation science (D&I)

Prostate Cancer Foundation 24th Annual Scientific Retreat

Washington, DC . October 4-7, 2017

Lecture Topic: Women in science panel, poster on crowdfunding in prostate cancer

Category: Women in science, Social Media

Grand Rounds at Washington University

St, Louis, Missouri. June 9, 2017

Lecture Topic: Social media in urology

Category: Social media

Grand Rounds at University of Pennsylvania

Philadelphia, Pennsylvania. May 18, 2017

Lecture Topic: Biomarkers in the diagnosis and management of localized prostate cancer

Category: Prostate Cancer

Prostate Cancer World Congress

Melbourne, Australia. August 2013

Category: Prostate Cancer

media

MedPage Today Interview on Viagra and Melanoma: Search for Link Inconclusive

6/2015 MedPage Today Interview on Viagra and Melanoma: Search for Link Inconclusive

http://www.medpagetoday.com/Urology/ErectileDysfunction/52272

Cancer Research and Oncology Virtual Conference: Lecture on Active Surveillance: Trends in Use, Patient Selection & Monitoring

10/2015 Cancer Research and Oncology Virtual Conference: Lecture on Active Surveillance: Trends in Use, Patient Selection & Monitoring September 30, 2015

Lecture topic: Active Surveillance: Trends in Use, Patient Selection and Monitoring

Category: prostate cancer

Location: online

Men Health

Key Papers

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.
Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

“Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.“

European Urology. 2015 Dec 29 epub. PMID: 26743040

Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040

A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.

Other Papers

Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P.

“Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.”

J Natl Cancer Inst. 2017 Aug 1;109(8). PMID: 29117385

Link: https://www.ncbi.nlm.nih.gov/pubmed/29117385

Loeb S, Stattin P.

“Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma.”

European Urology 2016 Jul 16 epub. PMID: 27436160.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27436160

Loeb S, Lambe M, Stattin P.

“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

Category: Prostate Cancer

Netherlands

Active Surveillance for Low Risk Prostate Cancer Conference

Amsterdam, Netherlands. February 2014

Lecture topic: Risk based prediction models for indolent Prostate Cancer

Category: Prostate Cancer

Erasmus University Medical Center

Rotterdam, Netherlands. November 2010

Lecture Topic: Prostate Cancer

Category: Prostate Cancer

news

WALL STREET JOURNAL ARTICLE ON PROSTATE CANCER TESTS

Sirius XM Channel 110 Doctor Radio

Dr. Loeb

Hosts the Men’s Health Show on US/Canada satellite radio Sirius XM channel 110

On Wednesdays from 6-8pm EST.

https://www.siriusxm.com/doctorradio/weeklyschedule

Report: Forbes article about Viagra & Melanoma

Ever since a paper was released last year detailing cases of melanoma found in men taking the billion-dollar erectile dysfunction (ED) blockbuster Viagra, urologist Stacy Loeb of New York University has been fielding questions from worried patients about whether they should risk the little blue pill…

North America

Nutrition Media

New York University Langone Health Webinar

Plant-Based Diet: Impact for Health, the Environment, and Social Justice (Jan 15, 2021)

PIX11 News

Eat It to Beat It’ Challenge Promotes Prostate Cancer Awareness Month (Sept 16, 2020)

Plant Powered Metro New York

A Key To Men’s Health is in the Kitchen (July 8, 2020)

Location: http://www.labroots.com/webcast/id/554

XXVII Congreso Venezolano de Urología, Congreso de Actualización en Urología Oncológica

Lecture topic: Nuevas marcardores en el cáncer de próstata (en español)

Dr Stacy Loeb presented on “Active Surveillance: Trends in Use, Patient Selection and Monitoring”

Category: prostate cancer

Location: http://www.labroots.com/webcast/id/554

XXVII Congreso Venezolano de Urología, Congreso de Actualización en Urología Oncológica

“Social media makes global urology meetings truly global.”

BJU International 2015 Feb; 115(2):175. PMID: 25604713

Link: http://www.ncbi.nlm.nih.gov/pubmed/25604713

Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.”

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

Other Papers

Bayne CE, Murphy DG, Loeb S.

“#Urology is Trending in Social Media.”

Reviews in Urology 2014; 16: 152. PMID: 25337049.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191639/

Other Papers

Carlsson S, Drevin L, Loeb S, Widmark A, Frank Lissbrant I, Robinson D, Johansson E, Stattin P, and Fransson P.

“Population-based study of long-term functional outcomes after prostate cancer treatment.”

BJU International 2014 epub. PMID: 25959859.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25959859

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013

Panama

Global Men’s Health Summit

Panama (Virtual). October 2020

Topic: Early Detection, Diagnosis and Risk Stratification of Prostate Cancer

Category: Prostate Cancer

XXXV Congreso Confederación Americana de Urología

Panama. October 2016

Lecture Topics: Prostate Cancer Active Surveillance, SelectMDx and ConfirmMDx Prostate Cancer Markers, Social Media in Urology

Categories: Prostate Cancer, Social Media

Philippines

Philippines Society of Uro-Oncology

Manila, Philippines. September 2014

PostTreatment

Using data from an online health community to examine the impact of prostate cancer on sleep.

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub. PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/

Untitled

Loeb S, Salter CA, Nelson CJ, Mulhall JP, Wittmann D.

“A Call to Arms: Increasing Our Understanding of the Impact of Prostate Cancer on the Sexual Health of Partners.”

Journal of Sexual Medicine. 2019 Dec 10 epub. PMID: 31836299.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31836299

Untitled

Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P.

“Opioid Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden.”

J Urol. 2019 Jul 17 epub. PMID:31584849

Link: https://www.ncbi.nlm.nih.gov/pubmed/31584849

Other Papers

Banks JA, McGuire BB, Loeb S, Shrestha S, Helfand BT, Catalona WJ.

“Bacteriuria and antibiotic resistance in catheter urine specimens following radical prostatectomy.”

Urologic Oncology 2012, epub Jan 25. PMID: 22285005.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22285005

Other Papers

Loeb S, Schaeffer EM, Chan DW, Carter HB, Walsh PC, and Sokoll LJ.

“Investigation of Human Anti-Mouse Antibodies As Potential Cause of Postprostatectomy PSA Elevation.”

Urology, May 2009; 73: 947.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19394489

Other Papers

Loeb S, Roehl KA, Viprikasit DP, and Catalona WJ.

“Long-Term Rates of Undetectable PSA with Initial Observation and Delayed Salvage Radiotherapy after Radical Prostatectomy.”

European Urology, July 2008; 54: 88.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18400368

Key Papers

Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, and Walsh PC.

“Can We Stop Prostate Specific Antigen Testing 10 Years After Radical Prostatectomy?”

Journal of Urology August 2011; 186: 500. PMID: 21679999.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21679999

Key Papers

Loeb S, Makarov DV, Schaeffer EM, Humphreys EB, and Walsh PC.

“Prostate-specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.”

Journal of Urology, July 2010; 184: 157.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20483148

Prostate

Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, Stroup SP.

“An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy.”

Journal of Urology 2017 Mar 29 epub. PMID: 28363690

Link: https://www.ncbi.nlm.nih.gov/pubmed/28363690

This is an updated American Urological Association White Paper with guidance on the prevention and treatment of prostate biopsy complications.

Loeb S.

“When is a Negative Prostate Biopsy Really Negative? Repeat Biopsies in Detection and Active Surveillance.”

Journal of Urology 2017 epub. PMID 28110035

Link: https://www.ncbi.nlm.nih.gov/pubmed/28110035

“When is a Negative Prostate Biopsy Really Negative? Repeat Biopsies in Detection and Active Surveillance.”

Journal of Urology 2017 epub. PMID 28110035

Link: https://www.ncbi.nlm.nih.gov/pubmed/28110035

Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.” BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.” European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871

Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S.

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

” Public online reporting from a nationwide population-based clinical prostate cancer register”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M. .

“Public online reporting from a nationwide population-based clinical prostate cancer register. “

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561

Untitled

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

“Health state utilities among contemporary prostate cancer patients on active surveillance.”

Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29732277

Untitled

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Untitled

Loeb S.

“Active Surveillance for Prostate Cancer.”

Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148

Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389

“Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869

Loeb S.

” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869

Loeb S, Dani H.

“Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

“Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub. PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub. PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

Loeb S, Meyer C, Krasnova A, Curnyn C, Reznor G, Lepor H, Kibel AS, Trinh QD.

“Risk of Small Bowel Obstruction After Robot-Assisted Versus Open Radical Prostatectomy.”

Journal of Endourology 2016 Sep 11 epub. PMID: 27615204

Link: https://www.ncbi.nlm.nih.gov/pubmed/27615204

Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.”

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

“A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub. PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Loeb S.

“When is a Negative Prostate Biopsy Really Negative? Repeat Biopsies in Detection and Active Surveillance.”

Journal of Urology 2017 epub. PMID 28110035

Link: https://www.ncbi.nlm.nih.gov/pubmed/28110035

Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P.

“Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.”

Journal of Surgical Oncology. 2016 Aug 11 epub. PMID: 27511833.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27511833

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489

“An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.”

Urology. 2016 Jul 19 epub. PMID: 27450937.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27450937

Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.”

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693

“Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology.”

2016 Nov 22. PMID: 27887941

Link: https://www.ncbi.nlm.nih.gov/pubmed/27887941

Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.” BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.” European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871

Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ.

“Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).”

Urology, June 2007; 69: 1143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203

Loeb S.

“Guideline of guidelines: prostate cancer screening.”

BJU International 2014 September; 114: 323.

PMID: 24981126.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?”

Journal of Clinical Oncology January 2011; 29: 464.
Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?”

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ.

“Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?”

BJU International, November 2009; 104: 1200.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19627283

Helfand BT, Loeb S, Kan D, Catalona WJ.

“Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.”

BJU International, June 2010 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20590552

Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ.

“Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.”

Journal of Urology, August 2010; 184: 501.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20620408

Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ.

“Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.”

Urology October 2011; 78: 970 .e 15-20.

PMID: 21820706.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3190015/

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November.

PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463

Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, and Loeb S.

“Prostate Cancer Risk Alleles are Associated with Prostate Cancer Tumor Volume and Prostate Size.”

Journal of Urology 2013; epub Dec 14.

PMID: 24345439

Link: http://www.ncbi.nlm.nih.gov/pubmed/24345439

Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT.

“A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease.”

BJU International 2014, June epub.

PMID: 24952954.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24952954

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.
Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR.

“Genomic Predictors of Outcome in Prostate Cancer.”

European Urology 2015 epub. PMID: 25913390.
Link: http://www.ncbi.nlm.nih.gov/pubmed/25913390

Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P.

“Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.”

Cancer Causes Control 2012;

December epub. PMID: 23266834.
Link: http://www.ncbi.nlm.nih.gov/pubmed/23266834

Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ.
“Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.”

Journal of Urology 2012; epub December. PMID: 23246478.
Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631301/

Key Articles

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.
Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

Key Article

Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S.

“Complications After Systematic, Random, and Image-guided Prostate Biopsy.”

European Urology. 2016 Aug 16 epub. PMID: 27543165.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27543165

Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.

PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975

Prostate Cancer - Lectures and Courses for Physicians

Prostate Cancer - Lectures for Patients/Community Outreach

Prostate Cancer - TV Appearances and Interviews

PSA Screening

“An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.”

Urology. 2016 Jul 19 epub. PMID: 27450937.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27450937

Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ.

“Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).”

Urology, June 2007; 69: 1143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203

Loeb S.

“Guideline of guidelines: prostate cancer screening.”

BJU International 2014 September; 114: 323.

PMID: 24981126.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?”

Journal of Clinical Oncology January 2011; 29: 464.
Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?”

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.

PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975

PSA Screening

“An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.”

Urology. 2016 Jul 19 epub. PMID: 27450937.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27450937

Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ.

“Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).”

Urology, June 2007; 69: 1143.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17572203

Loeb S.

“Guideline of guidelines: prostate cancer screening.”

BJU International 2014 September; 114: 323.

PMID: 24981126.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23567643

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?”

Journal of Clinical Oncology January 2011; 29: 464.
Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?”

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ.

“The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.”

British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

Link: http://www.ncbi.nlm.nih.gov/pubmed/24206066

Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT.

“Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.”

BJU International 2014 Jan epub.

PMID: 24712975

Link: http://www.ncbi.nlm.nih.gov/pubmed/24712975

PSAScreening

The Association of Veterans PSA Screening Rates with Changes in USPSTF Recommendations

Becker DJ, Rude T, Walter D, Wang C, Loeb S, Li H, Ciprut S, Kelly M, Zeliadt SB, Fagerlin A, Lepor H, Sherman S, Ravenell JE, Makarov DV.

“The Association of Veterans’ PSA Screening Rates with Changes in USPSTF Recommendations.”

J Natl Cancer Inst. 2020 Aug 14:djaa120. PMID: 32797212

Link: https://pubmed.ncbi.nlm.nih.gov/32797212/

“An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.”

Urology. 2016 Jul 19 epub. PMID: 27450937.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27450937

Loeb S.

“Will Changes to Prostate Cancer Screening Guidelines Preserve Benefits and Reduce Harms?”

European Urology 2016 April epub. PMID: 27090973.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27090973

Loeb S.

“Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening.”

Journal of Clinical Oncology 2016 Jun 20 epub. PMID: 27325846.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27325846

Key Papers

Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH.

“Baseline Prostate-Specific Antigen Testing at a Young Age.”

European Urology January 2012; 61: 1-7. PMID: 21862205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21862205

Key Papers

Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ.

“What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?”

Journal of Clinical Oncology January 2011; 29: 464.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21189374

Key Papers

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ.

“Prostate Specific Antigen Testing Among the Elderly: When to Stop?”

Journal of Urology, April 2009; 181: 1606.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19246059

Key Papers

Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB.

“Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age”

Urology, February 2006; 67: 316.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16442597

publications

Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ. “Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification.” European Urology 2014 Oct epub. PMID: 25457014

Link: http://www.ncbi.nlm.nih.gov/pubmed/25457014

Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P. “Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.” JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

Representation

Gender Bias in Medicine: Does it Exist at AUA Plenary Sessions?

Davuluri M, Barry E, Loeb S, Watts K.

“Does it Exist at AUA Plenary Sessions?”

Urology. 2020 May 18 epub. PMID: 32439553.

Link: https://pubmed.ncbi.nlm.nih.gov/32439553/

ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology

Loeb S, Byrne NK, Thakker S, Walter D, Katz MS.

“#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology.”

European Urology Focus. 2020 Apr 12:S2405-4569(20)30093-6. PMID: 32295754

Link: https://pubmed.ncbi.nlm.nih.gov/32295754/

Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/

Reviews/Editorials

Russia

Russian Ministry of Health, Institute of Urology

Moscow, Russia. March 2014

Lecture topic: PSA Screening Cost-Effectiveness, Prostate Cancer Markers

Category: Prostate Cancer

Social media

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology. 2021; S0090-4295(21)00266-1. PMID: 33775787

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/

Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines

Bhatt NR, Czarniecki SW, Borgmann H, van Oort IM, Esperto F, Pradere B, van Gurp M, Bloemberg J, Darraugh J, Rouprêt M, Loeb S, N’Dow J, Ribal MJ, Giannarini G; EAU

“Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines.”

Eur Urol Focus. 2020 Nov 7:S2405-4569(20)30292-3. PMID: 33172773

Link: https://pubmed.ncbi.nlm.nih.gov/33172773/

Quality of Bladder Cancer Information on YouTube

Loeb S, Reines K, Abu-Salha Y, French W, Butaney M, Macaluso JN Jr, Steinberg GD, Walter D, Byrne N, la Garza D, Smith AB.

“Quality of Bladder Cancer Information on YouTube.”

Eur Urol. 2020 Sep 30: S0302-2838(20)30706-5. PMID: 33010986

Link: https://pubmed.ncbi.nlm.nih.gov/33010986/

Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JY, Autrán Gómez AM, Ramasamy R, Loeb S, Rivas JG.

“Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees.”

Urology. 2020 Sep 18:S0090-4295(20)31139-0. PMID: 32950594

Link: https://pubmed.ncbi.nlm.nih.gov/32950594/

Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis

Sathianathen NJ, Lane Iii R, Murphy DG, Loeb S, Bakker C, Lamb AD, Weight CJ.

“Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis.”

Journal of Medical Internet Research. 2020 Apr 17;22(4):e12288. PMID: 32301733

Link: https://pubmed.ncbi.nlm.nih.gov/32301733/

#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology

Loeb S, Byrne NK, Thakker S, Walter D, Katz MS.

“#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology.”

European Urology Focus. 2020 Apr 12:S2405-4569(20)30093-6. PMID: 32295754

Link: https://pubmed.ncbi.nlm.nih.gov/32295754/

Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/

Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/

Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JYC, Autrán Gómez AM, Gomez Rivas J, Ramasamy R, Loeb S.

“Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists.”

BJU International. 2020 Mar 9 epub. PMID: 32147930.

Link: https://pubmed.ncbi.nlm.nih.gov/32147930/

Evaluating and Optimizing the Use of Social Media in Urology

Loeb S, Murphy DG.

“Evaluating and Optimizing the Use of Social Media in Urology.”

European Urology Focus. 2020 May 15;6(3):425-426. Epub 2020 Feb 29. PMID: 32127328.

Link: https://pubmed.ncbi.nlm.nih.gov/32127328/

Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub. PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/

Using data from an online health community to examine the impact of prostate cancer on sleep

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub. PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/

Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A.

“Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.

European Urology. 2018 Nov 27 epub. PMID: 30502104.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30502104

In this study, we examined the first 150 YouTube videos about prostate cancer, showing that the majority had potentially biased and/or misinformative information in the video or comments.

Borgmann H, Cooperberg M, Murphy D, Loeb S, N’Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C, Wirth M, Catto J, Kutikov A

“Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media”

European Urology 2018 Aug epub.. PMID: 30177286.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30177286

Loeb S, Taneja S, Walter D, Zweifach S, Byrne N.

“Crowd-Funding for Prostate Cancer and Breast Cancer. “

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29786946

Untitled

Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

“Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501

Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

“Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501

Ciprut S, Curnyn C, Davuluri M, Sternberg K, Loeb S.

“Twitter Activity Associated with US News and World Report Reputation Scores for Urology Departments.”

Urology. 2017 Jun 29 epub. PMID: 28669746.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28669746

Sternberg KM, Loeb SL, Canes D, Donnelly L, Tsai MH.

“The use of Twitter to facilitate sharing of clinical expertise in urology.”

J Am Med Inform Assoc. 2017 epub Jun 7. PMID: 28591771.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28591771

Loeb S, Stork B, Gold HT, Stout NK, Makarov DV, Weight C, Borgmann H.

“Tweet this: how advocacy for breast and prostate cancers stacks up on social media.”

BJU International 2017 May epub. PMID: 28471484

Link: http://www.ncbi.nlm.nih.gov/pubmed/2847148

O’Connor EM, Nason GJ, O’Kelly F, Manecksha RP, Loeb S.

“Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?”

BJU International 2017 Apr 18 epub. PMID: 28418091

Link: https://www.ncbi.nlm.nih.gov/pubmed/28418091

Loeb S, Roupret M, Van Oort I, N’dow J, Van Gurp M, Bloemberg J, Darraugh JA, Ribal M.

“Novel Use of Twitter to Disseminate and Evaluate Adherence with Clinical Guidelines by the European Association of Urology”.

BJU Int. 2017 Feb 7 epub. PMID: 28170154

Link: https://www.ncbi.nlm.nih.gov/pubmed/28170154

Other Papers

Loeb S. Editorial Comment on

“Digital Identity: Develop One Before You’re Given One”

Urology 2015; 85: 1222. PMID: 26099864.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26099864

Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.”

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.”

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

Use of Social Media in Urology: Data from the American Urological Association

Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE.

“Use of Social Media in Urology: Data from the American Urological Association.”

British Journal of Urology International 2013 epub Nov 26. PMID: 24274744

Link: http://www.ncbi.nlm.nih.gov/pubmed/24274744

Social Media

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology. 2021; S0090-4295(21)00266-1. PMID: 33775787

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/

Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines

Bhatt NR, Czarniecki SW, Borgmann H, van Oort IM, Esperto F, Pradere B, van Gurp M, Bloemberg J, Darraugh J, Rouprêt M, Loeb S, N’Dow J, Ribal MJ, Giannarini G; EAU

“Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines.”

Eur Urol Focus. 2020 Nov 7:S2405-4569(20)30292-3. PMID: 33172773

Link: https://pubmed.ncbi.nlm.nih.gov/33172773/

Quality of Bladder Cancer Information on YouTube

Loeb S, Reines K, Abu-Salha Y, French W, Butaney M, Macaluso JN Jr, Steinberg GD, Walter D, Byrne N, la Garza D, Smith AB.

“Quality of Bladder Cancer Information on YouTube.”

Eur Urol. 2020 Sep 30: S0302-2838(20)30706-5. PMID: 33010986

Link: https://pubmed.ncbi.nlm.nih.gov/33010986/

Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JY, Autrán Gómez AM, Ramasamy R, Loeb S, Rivas JG.

“Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees.”

Urology. 2020 Sep 18:S0090-4295(20)31139-0. PMID: 32950594

Link: https://pubmed.ncbi.nlm.nih.gov/32950594/

Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis

Sathianathen NJ, Lane Iii R, Murphy DG, Loeb S, Bakker C, Lamb AD, Weight CJ.

“Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis.”

Journal of Medical Internet Research. 2020 Apr 17;22(4):e12288. PMID: 32301733

Link: https://pubmed.ncbi.nlm.nih.gov/32301733/

#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology

Loeb S, Byrne NK, Thakker S, Walter D, Katz MS.

“#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology.”

European Urology Focus. 2020 Apr 12:S2405-4569(20)30093-6. PMID: 32295754

Link: https://pubmed.ncbi.nlm.nih.gov/32295754/

Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/

Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/

Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JYC, Autrán Gómez AM, Gomez Rivas J, Ramasamy R, Loeb S.

“Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists.”

BJU International. 2020 Mar 9 epub. PMID: 32147930.

Link: https://pubmed.ncbi.nlm.nih.gov/32147930/

Evaluating and Optimizing the Use of Social Media in Urology

Loeb S, Murphy DG.

“Evaluating and Optimizing the Use of Social Media in Urology.”

European Urology Focus. 2020 May 15;6(3):425-426. Epub 2020 Feb 29. PMID: 32127328.

Link: https://pubmed.ncbi.nlm.nih.gov/32127328/

Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub. PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/

Using data from an online health community to examine the impact of prostate cancer on sleep

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub. PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/

Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A.

“Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.

European Urology. 2018 Nov 27 epub. PMID: 30502104.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30502104

In this study, we examined the first 150 YouTube videos about prostate cancer, showing that the majority had potentially biased and/or misinformative information in the video or comments.

Borgmann H, Cooperberg M, Murphy D, Loeb S, N’Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C, Wirth M, Catto J, Kutikov A

“Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media”

European Urology 2018 Aug epub.. PMID: 30177286.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30177286

Loeb S, Taneja S, Walter D, Zweifach S, Byrne N.

“Crowd-Funding for Prostate Cancer and Breast Cancer. “

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29786946

Untitled

Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

“Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501

Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

“Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501

Ciprut S, Curnyn C, Davuluri M, Sternberg K, Loeb S.

“Twitter Activity Associated with US News and World Report Reputation Scores for Urology Departments.”

Urology. 2017 Jun 29 epub. PMID: 28669746.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28669746

Sternberg KM, Loeb SL, Canes D, Donnelly L, Tsai MH.

“The use of Twitter to facilitate sharing of clinical expertise in urology.”

J Am Med Inform Assoc. 2017 epub Jun 7. PMID: 28591771.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28591771

Loeb S, Stork B, Gold HT, Stout NK, Makarov DV, Weight C, Borgmann H.

“Tweet this: how advocacy for breast and prostate cancers stacks up on social media.”

BJU International 2017 May epub. PMID: 28471484

Link: http://www.ncbi.nlm.nih.gov/pubmed/2847148

O’Connor EM, Nason GJ, O’Kelly F, Manecksha RP, Loeb S.

“Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?”

BJU International 2017 Apr 18 epub. PMID: 28418091

Link: https://www.ncbi.nlm.nih.gov/pubmed/28418091

Loeb S, Roupret M, Van Oort I, N’dow J, Van Gurp M, Bloemberg J, Darraugh JA, Ribal M.

“Novel Use of Twitter to Disseminate and Evaluate Adherence with Clinical Guidelines by the European Association of Urology”.

BJU Int. 2017 Feb 7 epub. PMID: 28170154

Link: https://www.ncbi.nlm.nih.gov/pubmed/28170154

Other Papers

Loeb S. Editorial Comment on

“Digital Identity: Develop One Before You’re Given One”

Urology 2015; 85: 1222. PMID: 26099864.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26099864

Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.”

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV.

“Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.”

BJU International 2014 epub.

PMID: 24661474

Link: http://www.ncbi.nlm.nih.gov/pubmed/24661474

Use of Social Media in Urology: Data from the American Urological Association

Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE.

“Use of Social Media in Urology: Data from the American Urological Association.”

British Journal of Urology International 2013 epub Nov 26. PMID: 24274744

Link: http://www.ncbi.nlm.nih.gov/pubmed/24274744

Social Media - Interviews

ZERO Summit

Prostate Cancer and Fake News (March 2, 2021)

Malecare Prostate Cancer Patient Conference

Navigating Fake News about Prostate Cancer and Social Media (12/12/20)

Integrating Social Media as an Effective Teaching Tool for Patients – Stacy Loeb

11/2018 Integrating Social Media as an Effective Teaching Tool for Patients

Urology Times on Twitter in Urology

5/2014 Urology Times on Twitter in Urology

Twitter and Urology- Targeted Oncology Interview

5/2014 Twitter and Urology- Targeted Oncology Interview

Social Media - Lectures

Social Media for Urologists

EMPIRE Urology Lecture Series (5/6/20)

Lecture on Social Media in Medicine at International Continence Society in Rio de Janiero

10/2014 Lecture on Social Media in Medicine at International Continence Society in Rio de Janiero

SocialMedia

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology. 2021; S0090-4295(21)00266-1. PMID: 33775787

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/

Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines

Bhatt NR, Czarniecki SW, Borgmann H, van Oort IM, Esperto F, Pradere B, van Gurp M, Bloemberg J, Darraugh J, Rouprêt M, Loeb S, N’Dow J, Ribal MJ, Giannarini G; EAU

“Guidelines Office Dissemination Committee. A Systematic Review of the Use of Social Media for Dissemination of Clinical Practice Guidelines.”

Eur Urol Focus. 2020 Nov 7:S2405-4569(20)30292-3. PMID: 33172773

Link: https://pubmed.ncbi.nlm.nih.gov/33172773/

Quality of Bladder Cancer Information on YouTube

Loeb S, Reines K, Abu-Salha Y, French W, Butaney M, Macaluso JN Jr, Steinberg GD, Walter D, Byrne N, la Garza D, Smith AB.

“Quality of Bladder Cancer Information on YouTube.”

Eur Urol. 2020 Sep 30: S0302-2838(20)30706-5. PMID: 33010986

Link: https://pubmed.ncbi.nlm.nih.gov/33010986/

Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JY, Autrán Gómez AM, Ramasamy R, Loeb S, Rivas JG.

“Global Survey of the Roles and Attitudes Toward Social Media Platforms Amongst Urology Trainees.”

Urology. 2020 Sep 18:S0090-4295(20)31139-0. PMID: 32950594

Link: https://pubmed.ncbi.nlm.nih.gov/32950594/

Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis

Sathianathen NJ, Lane Iii R, Murphy DG, Loeb S, Bakker C, Lamb AD, Weight CJ.

“Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations- #SoMe_Impact Score: Observational Analysis.”

Journal of Medical Internet Research. 2020 Apr 17;22(4):e12288. PMID: 32301733

Link: https://pubmed.ncbi.nlm.nih.gov/32301733/

#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology

Loeb S, Byrne NK, Thakker S, Walter D, Katz MS.

“#ILookLikeAUrologist: Using Twitter to Discuss Diversity and Inclusion in Urology.”

European Urology Focus. 2020 Apr 12:S2405-4569(20)30093-6. PMID: 32295754

Link: https://pubmed.ncbi.nlm.nih.gov/32295754/

Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S.

“Racial Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.”

British Journal of Urology International. 2020 Apr 10 epub. PMID: 32275800

Link: https://pubmed.ncbi.nlm.nih.gov/32275800/

Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/

Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists

Dubin JM, Greer AB, Patel P, Carrion DM, Paesano N, Kettache RH, Haffaf M, Zouari S, Santillan D, Zotter Z, Chung A, Horie S, Koo KC, Teoh JYC, Autrán Gómez AM, Gomez Rivas J, Ramasamy R, Loeb S.

“Global Survey Evaluating Drawbacks of Social Media Usage for Practicing Urologists.”

BJU International. 2020 Mar 9 epub. PMID: 32147930.

Link: https://pubmed.ncbi.nlm.nih.gov/32147930/

Evaluating and Optimizing the Use of Social Media in Urology

Loeb S, Murphy DG.

“Evaluating and Optimizing the Use of Social Media in Urology.”

European Urology Focus. 2020 May 15;6(3):425-426. Epub 2020 Feb 29. PMID: 32127328.

Link: https://pubmed.ncbi.nlm.nih.gov/32127328/

Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub. PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/

Using data from an online health community to examine the impact of prostate cancer on sleep

Robbins R, Jean-Louis G, Chanko N, Combs P, Byrne N, Loeb S.

“Using data from an online health community to examine the impact of prostate cancer on sleep.”

British Journal of Urology International. 2020 Jan 3 epub. PMID: 31899938.

Link: https://pubmed.ncbi.nlm.nih.gov/31899938/

Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A.

“Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube.

European Urology. 2018 Nov 27 epub. PMID: 30502104.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30502104

In this study, we examined the first 150 YouTube videos about prostate cancer, showing that the majority had potentially biased and/or misinformative information in the video or comments.

Borgmann H, Cooperberg M, Murphy D, Loeb S, N’Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C, Wirth M, Catto J, Kutikov A

“Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media”

European Urology 2018 Aug epub.. PMID: 30177286.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30177286

Loeb S, Taneja S, Walter D, Zweifach S, Byrne N.

“Crowd-Funding for Prostate Cancer and Breast Cancer. “

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29786946

Untitled

Loeb S, Katz MS, Langford A, Byrne N, Ciprut S.

“Prostate Cancer and Social Media.”

Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29643501

Ciprut S, Curnyn C, Davuluri M, Sternberg K, Loeb S.

“Twitter Activity Associated with US News and World Report Reputation Scores for Urology Departments.”

Urology. 2017 Jun 29 epub. PMID: 28669746.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28669746

Sternberg KM, Loeb SL, Canes D, Donnelly L, Tsai MH.

“The use of Twitter to facilitate sharing of clinical expertise in urology.”

J Am Med Inform Assoc. 2017 epub Jun 7. PMID: 28591771.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28591771

Loeb S, Stork B, Gold HT, Stout NK, Makarov DV, Weight C, Borgmann H.

“Tweet this: how advocacy for breast and prostate cancers stacks up on social media.”

BJU International 2017 May epub. PMID: 28471484

Link: http://www.ncbi.nlm.nih.gov/pubmed/2847148

O’Connor EM, Nason GJ, O’Kelly F, Manecksha RP, Loeb S.

“Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?”

BJU International 2017 Apr 18 epub. PMID: 28418091

Link: https://www.ncbi.nlm.nih.gov/pubmed/28418091

Loeb S, Roupret M, Van Oort I, N’dow J, Van Gurp M, Bloemberg J, Darraugh JA, Ribal M.

“Novel Use of Twitter to Disseminate and Evaluate Adherence with Clinical Guidelines by the European Association of Urology”.

BJU Int. 2017 Feb 7 epub. PMID: 28170154

Link: https://www.ncbi.nlm.nih.gov/pubmed/28170154

Borghmann H, Loeb S, Salem J, Thomas C, Haferkamp A, Murphy DG, Tsaur I.

“Activity, content, contributors, and influencers of the twitter discussion on urologic oncology.”

Urologic Oncology 2016 epub. PMID: 27036217.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27036217

Mata DA, Tilak G, Loeb S, Ramasamy R.

“Curating a Digital Identity: What Urologists Need to Know About Social Media.”

Urology 2016 Jul 6 epub. PMID: 27395795.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27395795

Borgmann H, Woelm JH, Merseburger A, Nestler T, Salem J, Brandt MP, Haferkamp A, Loeb S.

“Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference.”

Canadian Urological Association Journal 2016 Jan-Feb;10(1-2):39-44. PMID: 26977205.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26977205

World Congress of Endourology 2016

Capetown, South Africa. November 8-12, 2016
Lecture topic: Social media in urology
Category: Social Media

Spain

Challenges in Laparoscopy and Robotics

Barcelona, Spain – July 3-4, 2019

Lecture Topics: Social Media in Prostate Cancer, Robotic Prostatectomy Moderation

Category: prostate cancer, surgical technique, social media

European Association of Urology 2015

Madrid, Spain. March 2015

Lecture Topics: Prognostic Factors in the Prostate Histology, Social Media

Categories: Prostate Cancer, Social Media, Erectile Dysfunction

International Genitourinary Cancer Symposium (IGUCC 6)

Madrid, Spain. February 2014

Lecture topic: Smarter Prostate Cancer Screening

Category: Prostate Cancer

Staging

A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study

Ciprut SE, Kelly MD, Walter D, Hoffman R, Becker DJ, Loeb S, Sedlander E, Tenner CT, Sherman SE, Zeliadt SB, Makarov DV.

“A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study.”

Urology. 2020 Nov;145:113-119. Epub 2020 Jul 25.PMID: 32721517.

Link: https://pubmed.ncbi.nlm.nih.gov/32721517/

Untitled

Drangsholt S, Walter D, Ciprut S, Lepor A, Sedlander E, Curnyn C, Loeb S, Malloy P, Winn AN, Makarov DV.

” Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.”

Urologic Oncology 2019 Feb;37(2):145-149. PMID: 30578160.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30578160

Untitled

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

” Public online reporting from a nationwide population-based clinical prostate cancer register”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561

“Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869

Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P.

“Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.”

Journal of Surgical Oncology. 2016 Aug 11 epub. PMID: 27511833.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27511833

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.”

European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871

Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.”

BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology, January 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013

Reviews/Editorials

Loeb S.

“Editorial comment on ‘Current Ability of Multiparametric Prostate MRI and Targeted Biopsy to Improve the Detection of Prostate Cancer’”

Urology Practice 2014 May; 1: 20.

Other Papers

Graif T, Yu Y, Loeb S, Gashti SN, Griffin S, Han M, Roehl KA, Suarez BK, and Catalona WJ.

“Underdiagnosis and Overdiagnosis of Prostate Cancer.”

Journal of Urology 2007; 178: 88.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17499308

Reviews/Editorials

Loeb S and Partin AW.

“Imaging Utilization for the Staging of Clinically Localized Prostate Cancer.”

Reviews in Urology 2011; 13: 63. PMID: 21845110.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155872/

Other Papers

Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ.

“Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.”

Urology 2007; 70: 1117.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030

Reviews/Editorials

Loeb S.

“Editorial Comment on ‘Impact of Positive Apical Surgical Margins on Likelihood of Biochemical Recurrence After Radical Prostatectomy.”

Journal of Urology, December 2009; 182: 2701.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19836758

Other Papers

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology, March 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576

Key Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

Reviews/Editorials

Loeb S and Catalona WJ.

“What is the prognostic impact of positive surgical margins in surgically treated prostate cancer?”

Nature Clinical Practice Urology, August 2006; 3: 418.

Link: http://www.nature.com/nrurol/journal/v3/n8/full/ncpuro0549.html

Other Papers

Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ.

“Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression”

Urology, July 2006; 68: 99.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410

Key Papers

Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P.

“Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging.”

Journal of the National Cancer Institute (JNCI) 2013 July epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23853055

Staging

A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study

Ciprut SE, Kelly MD, Walter D, Hoffman R, Becker DJ, Loeb S, Sedlander E, Tenner CT, Sherman SE, Zeliadt SB, Makarov DV.

“A Clinical Reminder Order Check Intervention to Improve Guideline-concordant Imaging Practices for Men With Prostate Cancer: A Pilot Study.”

Urology. 2020 Nov;145:113-119. Epub 2020 Jul 25.PMID: 32721517.

Link: https://pubmed.ncbi.nlm.nih.gov/32721517/

Untitled

Drangsholt S, Walter D, Ciprut S, Lepor A, Sedlander E, Curnyn C, Loeb S, Malloy P, Winn AN, Makarov DV.

” Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer.”

Urologic Oncology 2019 Feb;37(2):145-149. PMID: 30578160.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30578160

Untitled

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

” Public online reporting from a nationwide population-based clinical prostate cancer register”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561

“Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869

Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P.

“Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.”

Journal of Surgical Oncology. 2016 Aug 11 epub. PMID: 27511833.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27511833

Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P.

“Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.”

European Urology. 2015 Dec 17 epub. PMID: 26707871

Link: http://www.ncbi.nlm.nih.gov/pubmed/26707871

Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L.

“The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012.”

BJU International. 2016 Feb 25 epub. PMID:26918298.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26918298

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ.

“Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?”

Journal of Urology, January 2007; 177: 102.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17162013

Reviews/Editorials

Loeb S.

“Editorial comment on ‘Current Ability of Multiparametric Prostate MRI and Targeted Biopsy to Improve the Detection of Prostate Cancer’”

Urology Practice 2014 May; 1: 20.

Other Papers

Graif T, Yu Y, Loeb S, Gashti SN, Griffin S, Han M, Roehl KA, Suarez BK, and Catalona WJ.

“Underdiagnosis and Overdiagnosis of Prostate Cancer.”

Journal of Urology 2007; 178: 88.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17499308

Reviews/Editorials

Loeb S and Partin AW.

“Imaging Utilization for the Staging of Clinically Localized Prostate Cancer.”

Reviews in Urology 2011; 13: 63. PMID: 21845110.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155872/

Other Papers

Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ.

“Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.”

Urology 2007; 70: 1117.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18158030

Reviews/Editorials

Loeb S.

“Editorial Comment on ‘Impact of Positive Apical Surgical Margins on Likelihood of Biochemical Recurrence After Radical Prostatectomy.”

Journal of Urology, December 2009; 182: 2701.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19836758

Other Papers

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology, March 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576

Key Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

Reviews/Editorials

Loeb S and Catalona WJ.

“What is the prognostic impact of positive surgical margins in surgically treated prostate cancer?”

Nature Clinical Practice Urology, August 2006; 3: 418.

Link: http://www.nature.com/nrurol/journal/v3/n8/full/ncpuro0549.html

Other Papers

Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ.

“Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression”

Urology, July 2006; 68: 99.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16806410

Key Papers

Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P.

“Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging.”

Journal of the National Cancer Institute (JNCI) 2013 July epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23853055

Surgical

National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses.

Bjurlin MA, Walter D, Taksler GB, Huang WC, Wysock JS, Sivarajan G, Loeb S, Taneja SS, Makarov DV.

“National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses.”

Urology 2013; 82: 1283-9. PMID: 24295245.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24295245

Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.

Loeb S, Semins MJ, and Matlaga BR.

“Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.”

Urology, August 2012; 80: 474. PMID: 22857764.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22857764

Radical Retropubic Prostatectomy: Comparison of the Open and Robotic Approaches for Treatment of Prostate Cancer.

Tosoian J and Loeb S.

“Radical Retropubic Prostatectomy: Comparison of the Open and Robotic Approaches for Treatment of Prostate Cancer.”

Reviews in Urology 2012; 14: 1-8. PMID: 23172996.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502048/

The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary.

Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S.

“The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary.”

Journal of Urology epub October 18, 2012. PMID: 23083655.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23083655

Complications of Pelvic Lymphadenectomy: Do the Risks Outweigh the Benefits?

Loeb S, Partin AW, and Schaeffer EM.

“Complications of Pelvic Lymphadenectomy: Do the Risks Outweigh the Benefits?”

Reviews in Urology, Winter 2010; 12: 20.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859138/

Open versus minimally invasive radical prostatectomy.

Loeb S and Partin AW.

“Open versus minimally invasive radical prostatectomy.”

Reviews in Urology, Winter 2010; 12: 20.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859144/

The Case for Open Radical Prostatectomy.

Schaeffer EM, Loeb S, and Walsh PC.

“The Case for Open Radical Prostatectomy.”

Urological Clinics of North America 2010; 37: 49.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20152519

Reducing Blood Loss in Open Radical Retropubic Prostatectomy with Prophylactic Periprostatic Sutures.

Carvalhal GF, Griffin CR, Kan D, Loeb S, and Catalona WJ.

“Reducing Blood Loss in Open Radical Retropubic Prostatectomy with Prophylactic Periprostatic Sutures.”

BJU International 2010; 105: 1222.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19888968

Benign Prostate Glands at the Bladder Neck Margin in Robotic vs. Open Radical Prostatectomy.

Loeb S, Epstein JI, Ross AE, Schultz L, Humphreys EB, and Jarow JP.

“Benign Prostate Glands at the Bladder Neck Margin in Robotic vs. Open Radical Prostatectomy.”

BJU International 2010; 104: 1446

Link: http://www.ncbi.nlm.nih.gov/pubmed/20346031

Management of Distal Ureter in Laparoscopic Nephroureterectomy- A Comprehensive Review of Techniques.

Macejko AM, Pazona JF, Loeb S, Kimm S, and Nadler RB.

“Management of Distal Ureter in Laparoscopic Nephroureterectomy- A Comprehensive Review of Techniques.”

Urology, July 2008 epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18602140

Thoracic Complications of Urological Laparoscopy: Correlation Between Radiographic Findings and Clinical Manifestations.

Zhao LC, Han JS, Loeb S, Tenggardjaja C, Rubenstein R, Smith ND, and Nadler RB.

“Thoracic Complications of Urological Laparoscopy: Correlation Between Radiographic Findings and Clinical Manifestations.”

J Endourol, April 2008; 22: 607.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18419207

The Use of BioGlue in Laparoscopic Partial Nephrectomy.

Nadler RB, Loeb S, and Vardi IY.

“The Use of BioGlue in Laparoscopic Partial Nephrectomy.”

Urology, August 2006; 68: 416.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16904466

A Prospective Study on Laparoscopic Radical Nephrectomy: Is Transperitoneal, Retroperitoneal, or Hand-Assisted the Best Approach?

Nadler RB, Loeb S, Clemens JQ, Batler RA, Gonzalez CM, and Vardi IY.

“A Prospective Study on Laparoscopic Radical Nephrectomy: Is Transperitoneal, Retroperitoneal, or Hand-Assisted the Best Approach?”

Journal of Urology, April 2006; 175: 1230.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16515966

Surgical Technique

Sweden

Uppsala University Honorary Doctorate

Uppsala, Sweden. January 2020

Lecture Topic: International Collaboration Using Swedish Registry Data to Improve Health

Category: Prostate Cancer, Men’s Health, Drug Safety

European Association of Urology 2014 Congress

Stockholm, Sweden. April 2014

Lecture Topic: Invited lecture on Standardizing Report and Outcome of Surgery in Prostate Cancer

Category: Prostate Cancer

ACME meeting

Hemavan, Sweden. January 2012

Lecture topic: Prostate Cancer Risk among immigrants to Sweden

Category: Prostate Cancer

Switzerland

Hot Topics in Uro-Oncology

Zurich, Switzerland – January 25, 2019

Lecture Topic: Prostate Cancer Screening in the Era of MRI and Novel Biomarkers

Category: Prostate Cancer, MRI, Screening, Markers

Tel Aviv - Israel

Telemedicine

Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study

Dubin JM, Wyant WA, Balaji NC, Ong WL, Kettache RH, Haffaf M, Zouari S, Santillan D, Autrán Gómez AM, Sadeghi-Nejad H, Loeb S, Borin JF, Gomez Rivas J, Grummet J, Ramasamy R, Teoh JYC.

“Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study.”

J Med Internet Res. 2020 Nov 5;22(11):e21875. PMID: 33031047

Link: https://pubmed.ncbi.nlm.nih.gov/33031047/

Telemedicine and Smart Working: Recommendations of the European Association of Urology

Rodriguez Socarrás M, Loeb S, Teoh JY, Ribal MJ, Bloemberg J, Catto J, N’Dow J, Van Poppel H, Gómez Rivas J.

“Telemedicine and Smart Working: Recommendations of the European Association of Urology.”

Eur Urol. 2020 Dec;78(6):812-819. PMID: 32654801

Link: https://pubmed.ncbi.nlm.nih.gov/32654801/

The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R, O’Brien T, Odisho AY, Powles T, Skolarus TA, Smith AB, Szabados B, Klaassen Z, Spratt DE.

“The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.”

Eur Urol. 2020 Nov;78(5):731-742. PMID: 32893062.

Link: https://pubmed.ncbi.nlm.nih.gov/32893062/

test

The Netherlands

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561/a>

Loeb S.

“Educational intervention in prostate cancer.”

BJU International 2017 Nov; 120(5B):E3. PMID: 29105995

Link: https://www.ncbi.nlm.nih.gov/pubmed/29105995

Loeb S, Meyer C, Krasnova A, Curnyn C, Reznor G, Lepor H, Kibel AS, Trinh QD.

“Risk of Small Bowel Obstruction After Robot-Assisted Versus Open Radical Prostatectomy.”

Journal of Endourology 2016 Sep 11 epub. PMID: 27615204

Link: https://www.ncbi.nlm.nih.gov/pubmed/27615204

“Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology.”

2016 Nov 22. PMID: 27887941

Link: https://www.ncbi.nlm.nih.gov/pubmed/27887941

Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, Stattin P, Akre O.

“Ninety-Day Postoperative Mortality after Robot-assisted Laparoscopic Prostatectomy and Retropubic Radical Prostatectomy. Nation-wide population-based study.”

BJU International 2016 Jan 13 epub. PMID: 26762928

Link: http://www.ncbi.nlm.nih.gov/pubmed/26762928

Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M.

“Public online reporting from a nationwide population-based clinical prostate cancer register.”

BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29577561/a>

Loeb S.

“Educational intervention in prostate cancer.”

BJU International 2017 Nov; 120(5B):E3. PMID: 29105995

Link: https://www.ncbi.nlm.nih.gov/pubmed/29105995

Loeb S, Meyer C, Krasnova A, Curnyn C, Reznor G, Lepor H, Kibel AS, Trinh QD.

“Risk of Small Bowel Obstruction After Robot-Assisted Versus Open Radical Prostatectomy.”

Journal of Endourology 2016 Sep 11 epub. PMID: 27615204

Link: https://www.ncbi.nlm.nih.gov/pubmed/27615204

“Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology.”

2016 Nov 22. PMID: 27887941

Link: https://www.ncbi.nlm.nih.gov/pubmed/27887941

Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, Stattin P, Akre O.

“Ninety-Day Postoperative Mortality after Robot-assisted Laparoscopic Prostatectomy and Retropubic Radical Prostatectomy. Nation-wide population-based study.”

BJU International 2016 Jan 13 epub. PMID: 26762928

Link: http://www.ncbi.nlm.nih.gov/pubmed/26762928

Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998

Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ.

“Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen- Based Screening”

Journal of Urology 2006; 175: 902.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16469576

Uncategorized

Dr Loeb on Tests for the Management of Prostate Cancer (published June 6, 2017)

OncLive: Dr Loeb on Tests for the Management of Prostate Cancer (published June 6, 2017)

https://www.youtube.com/watch?v=RexdoXUbF98

Dr Loeb on Active Surveillance for Prostate Cancer (published May 12, 2017)

OncLive: Dr Loeb on Active Surveillance for Prostate Cancer (published May 12, 2017)

Prostate Cancer Foundation: Women in Prostate Cancer Research- Dr Stacy Loeb (published March 17, 2017)

https://www.youtube.com/watch?v=PJIEald08kU&t=37s

Upcoming

Sirius XM Channel 110 Doctor Radio Host

Dr Stacy Loeb hosts the Men’s Health Show on US/Canada Satellite Radio (SiriusXM Channel 110) on Wednesdays from 6-8pmEST.

Next shows: August 30, September 27, October 25

Uro-Oncology

UroOncology

Quality of Bladder Cancer Information on YouTube

Loeb S, Reines K, Abu-Salha Y, French W, Butaney M, Macaluso JN Jr, Steinberg GD, Walter D, Byrne N, la Garza D, Smith AB.

“Quality of Bladder Cancer Information on YouTube.”

Eur Urol. 2020 Sep 30: S0302-2838(20)30706-5. PMID: 33010986

Link: https://pubmed.ncbi.nlm.nih.gov/33010986/

Controversies in Management of High-Risk Prostate and Bladder Cancer.

Loeb S, Ribal MJ.

“Controversies in Management of High-Risk Prostate and Bladder Cancer.”

BJU International 2015 Nov; 116: 675. PMID: 26449166.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26449166

Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers.

Bangma CH, Loeb S, Susstra M, Zhu X, Bouazzaoui SE, Refos J, Van Der Keur KA, Tijn S, Franken CG, van Leenders GJ, Zwarthoff EC, Roobol MJ.

“Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers.”

European Urology 2013 epub March 4. PMID: 23478169

Link: http://www.ncbi.nlm.nih.gov/pubmed/23478169

National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses.

Bjurlin MA, Walter D, Taksler GB, Huang WC, Wysock JS, Sivarajan G, Loeb S, Taneja SS, Makarov DV.

“National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses.”

Urology 2013; 82: 1283-9. PMID: 24295245.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24295245

Is Prostate Specific Antigen Surveillance Necessary in Men with Benign Prostate Pathology Following Radical Cystoprostatectomy for Bladder Cancer?

Bivalacqua TJ, Loeb S, Pierorazio PM, Schoenberg MP, Partin AW, Guzzo TJ.

“Is Prostate Specific Antigen Surveillance Necessary in Men with Benign Prostate Pathology Following Radical Cystoprostatectomy for Bladder Cancer?”

Urologia Internationalis epub November 2010; 85: 466.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21071926

A Case of Gastrointestinal Stromal Tumor Diagnosed on Prostate Biopsy.

Loeb S, Lotan T, Thornton K, and Schoenberg MP.

“A Case of Gastrointestinal Stromal Tumor Diagnosed on Prostate Biopsy.”

Nature Clinical Practice Urology, December 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/19048005

Thoracic Complications of Urological Laparoscopy: Correlation Between Radiographic Findings and Clinical Manifestations.

Zhao LC, Han JS, Loeb S, Tenggardjaja C, Rubenstein R, Smith ND, and Nadler RB.

“Thoracic Complications of Urological Laparoscopy: Correlation Between Radiographic Findings and Clinical Manifestations.”

J Endourol 2008; 22: 607.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18419207

Management of Distal Ureter in Laparoscopic Nephroureterectomy- A Comprehensive Review of Techniques.

Macejko AM, Pazona JF, Loeb S, Kimm S, and Nadler RB.

“Management of Distal Ureter in Laparoscopic Nephroureterectomy- A Comprehensive Review of Techniques.”

Urology 2008 (epub).

Link: http://www.ncbi.nlm.nih.gov/pubmed/18602140

Pathologic Findings and Clinical Outcomes of Patients Undergoing Retroperitoneal Lymph Node Dissection Following Multiple Chemotherapy Regimens for Metastatic Testicular Germ Cell Tumors.

Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, and Sheinfeld J.

“Pathologic Findings and Clinical Outcomes of Patients Undergoing Retroperitoneal Lymph Node Dissection Following Multiple Chemotherapy Regimens for Metastatic Testicular Germ Cell Tumors.”

Cancer, February 2007; 109: 528.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17177200

A Prospective Study on Laparoscopic Radical Nephrectomy: Is Transperitoneal, Retroperitoneal, or Hand-Assisted the Best Approach?

Nadler RB, Loeb S, Clemens JQ, Batler RA, Gonzalez CM, and Vardi IY.

“A Prospective Study on Laparoscopic Radical Nephrectomy: Is Transperitoneal, Retroperitoneal, or Hand-Assisted the Best Approach?”

Journal of Urology, April 2006; 175: 1230.

Link: http://www.ncbi.nlm.nih.gov/pubmed/16515966

The Use of BioGlue in Laparoscopic Partial Nephrectomy.

Nadler RB, Loeb S, and Vardi IY.

“The Use of BioGlue in Laparoscopic Partial Nephrectomy.”

Malibu, CA – November 7, 2019

Lecture Topic: Role of Social Media in Science Information

Category: Social media

Division of General Internal Medicine, NYU

NY, NY – October 8, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

Inspire Seminar Series, Manhattan Veterans Affairs

NY, NY – October 17, 2019
Lecture Topic: The Promise and Peril of Social Media in Prostate Cancer
Category: Social Media, Prostate Cancer

Prostate Cancer Foundation 2019 Retreat

Carlsbad, CA – October 1-4, 2019

Lecture Topics: Panel at the PCF Women’s Forum on Navigating Confidence; Moderator and Presenter about Online Information and Side Effects at PCF-Us TOO Patient Advocacy Session

Category: Women In Science, Prostate Cancer, Social Media, Survivorship

American Association of Clinical Urologists (AACU)

Washington DC – October 12-14, 2019

Lecture Topic: Online Presence for Urologists, Clinical Urology in 2019 (Panel)

Category: Social Media, Urology

Hackensack University Medical Center Visiting Professor

Hackensack, New Jersey – October 15, 2019

Lecture Topic: Social Media in Medicine

Category: Social Media

Northeastern Section of the American Urological Association

Syracuse, NY – September, 2019

Lecture topics: Reducing prostate cancer overtreatment with active surveillance; Biomarkers- how do we use them

Category: Prostate Cancer, Active Surveillance, Markers

American Urological Association 2019 Annual Meeting

Chicago, IL – May 2-5, 2019

Lecture Topics: Plenary on Top 10 Apps for Wellness, Work and Study; Prostate Cancer Update Course

Category: Apps, Social Media, Prostate Cancer

University of California San Francisco Urology Grand Rounds

San Francisco, CA – January 9, 2019

Lecture Topic: Social Media in Urology

Category: Social Media

Henry Ford Vattikuti Urology Institute Visiting Professor

Detroit, MI – December 11-12, 2018

Lecture topics: Active Surveillance, Social Media

Category: Prostate cancer, active surveillance, social media

American Urological Association 2018 Meeting

San Francisco, CA. May 18-22, 2018

Lecture topic: Optimizing Technique and Selection for Prostate Biopsy, Prostate Cancer Press Conferences, Prostate Cancer Updates Course

Category: Prostate Cancer

LA Live Advanced Robotic & Open Surgery Symposium

Los Angeles, CA. May 16-17, 2018

Lecture topic: Active surveillance for prostate cancer, Live surgery panel

Category: Prostate Cancer

3rd Annual USC L.A. Live Practical Urology Conference

Los Angeles, California . February 1-3, 2018

Lecture Topic:Using markers to improve selection for prostate biopsy, prostate biopsy complications

Category: Prostate Cancer

Society of Women in Urology

Las Vegas, Nevada. January 19-21, 2018

Lecture Topic: Genomic markers for prostate cancer, social media

Category: Prostate Cancer, Social Media

Chairman’s Rounds at Johns Hopkins Hospital

Baltimore, Maryland. November 16, 2017

Lecture Topic: Update on active surveillance and dissemination of knowledge in urology

Category: prostate cancer, social media, dissemination and implementation science (D&I)

Prostate Cancer Foundation 24th Annual Scientific Retreat

Washington, DC . October 4-7, 2017

Lecture Topic: Women in science panel, poster on crowdfunding in prostate cancer

Category: Women in science, Social Media

Grand Rounds at Washington University

St, Louis, Missouri. June 9, 2017

Lecture Topic: Social media in urology

Category: Social media

Grand Rounds at University of Pennsylvania

Philadelphia, Pennsylvania. May 18, 2017

Lecture Topic: Biomarkers in the diagnosis and management of localized prostate cancer

Category: Prostate Cancer

Royal Society of Medicine Winter Meeting

Lake Tahoe (Northstar, California). January 28-30, 2017

Lecture Topics: Urology Highlights of 2016 as Seen Through the Eyes of Twitter, What Has Happened to Screening for Prostate Cancer in the US?

Categories: Social Media, Prostate Cancer

LA Live 2nd University of Southern California Annual Conference: Practical Urology

Los Angeles, California. January 26, 2017

Lecture Topic: Prostate Cancer Markers

Category: Prostate Cancer Markers

Prostate Cancer Foundation 2016 Scientific Retreat

Carlsbad, California. October 26-29, 2016

Lecture topic: Social media in prostate cancer

Category: Social Media

Advanced Robotic Urology and Prostate Cancer Update (Napa, California)Advanced Robotic Urology and Prostate Cancer Update

Napa, California. August 2016

Lecture Topics: Who to Biopsy and Rebiopsy, Tissue-Based Markers for Prostate Cancer Risk Stratification, Biomarker Panel

Category: Prostate Cancer, Biopsy, Markers

Visiting professor at University of Rochester

Rochester, New York. June 8, 2016

Lecture Topic: Markers in Prostate Cancer Screening and Active Surveillance

Category: Prostate Cancer

American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

Chicago, Illinois. June 3-5, 2016

Lecture Topic: Active Surveillance for Prostate Cancer

Category: Prostate Cancer

American Urological Association (AUA) 2016 Annual Meeting

USA. May 2016

Categories: Prostate Cancer, Men’s Health, Testosterone, Social Media

Visiting Professor at SUNY Downstate

New York. March 23, 2016

Lecture Topics: Prostate Biopsy Indications, Active Surveillance

Category: Prostate Cancer

UNIVERSITY OF SOUTHERN CALIFORNIA INSTITUTE OF UROLOGY 1ST ANNUAL PRACTICAL UROLOGY CONFERENCE

California, USA. February 4-6, 2016

Lecture Topics: Prostate Xancer surgical Masterclass, Biomarkers and Active Surveillance for Prostate Cancer, Social Media in Urology

Category: Prostate Cancer, Social Media

Society of Women in Urology (SWIU)

USA. January 22-23, 2016

Lecture Topic: Serum, Urine and Tissue Markers in Prostate Cancer

Category: Prostate cancer

26th International Prostate Cancer Update (IPCU)

Colorado, USA. January 20-22, 2016

Lecture Topics: When to do prostate biopsy: Role for PSA and novel biomarkers

Category: Prostate cancer

Visiting Professor at the Division of Urology at Albany Medical College

USA. October 2015

Lecture Topics: Markers in Prostate Cancer Screening and Active Surveillance, Social Media in Urology

Categories: Prostate cancer, Social media

Florida Urological Society meeting

Florida, USA. September 2015

Lectures topics: 1) The Dilemma of an Elevated PSA: The Role of New Biomarkers to Determine When to Biopsy, 2) 4K Score, 3) Social Media in Urology

Categories: Prostate Cancer, Social Media

NYC Urological Research Society 2016

New York, Usa. Sptember 2015

Lecture topic: Decipher test in potential candidates for Active Surveillance

Category: Prostate Cancer, Active Surveillance, Markers

FDUS Future Directions in Urology

Colorado, USA. August 2015

Lecture topic: Social Media in Urology

Category: Social Media

Video

NYU Langone Health

Spotlight on Prostate Cancer (October 6, 2020)

ZERO Summit

Prostate Cancer and Fake News (March 2, 2021)

Malecare Prostate Cancer Patient Conference

Navigating Fake News about Prostate Cancer and Social Media (12/12/20)

Fans for the Cure Stay in the Game Podcast

Early Detection of Prostate Cancer (9/30/20)

Link: https://fansforthecure.org/podcast/early-detection-of-prostate-cancer/

Social Media for Urologists

EMPIRE Urology Lecture Series (5/6/20)

International Volunteers in Urology Virtual Visiting Professor Panel Discussion on COVID-19 (5/4/20)

New York University Langone Health Webinar

Plant-Based Diet: Impact for Health, the Environment, and Social Justice (Jan 15, 2021)

PIX11 News

Eat It to Beat It’ Challenge Promotes Prostate Cancer Awareness Month (Sept 16, 2020)

Plant Powered Metro New York

A Key To Men’s Health is in the Kitchen (July 8, 2020)

Bill Martinez Live – Empowering Men to Take Charge of Their Life for Men’s Health Month

https://billmartinezlive.com/stacy-loeb-june-13-2019/

Integrating Social Media as an Effective Teaching Tool for Patients – Stacy Loeb

11/2018 Integrating Social Media as an Effective Teaching Tool for Patients

Use of Conservative Management for Low-Risk Prostate Cancer

https://www.urotoday.com/video-lectures/prostate-cancer/video/970-embedded-media2018-06-14-16-15-42.html

Dr. Loeb on Determining Beneficial Test Options for Prostate Cancer (published July 2017)

OncLive: Dr. Loeb on Determining Beneficial Test Options for Prostate Cancer (published July 2017)

Dr. Loeb on the Impact of Additional Testing for Prostate Cancer

OncLive: Dr. Loeb on the Impact of Additional Testing for Prostate Cancer (published Oct 11, 2017)

Dr Loeb on the Results of Active Surveillance for Prostate Cancer (published August 2017)

OncLive: Dr Loeb on the Results of Active Surveillance for Prostate Cancer (published August 2017)

OncLive: Dr. Loeb on Tests for the Management of Prostate Cancer (published June 6, 2017)

Dr Loeb on Active Surveillance for Prostate Cancer (published May 12, 2017)

OncLive: Dr Loeb on Active Surveillance for Prostate Cancer (published May 12, 2017)

Lecture on “When to Biopsy: The Role for PSA and Novel Biomarkers”

01/2016

Lecture on “When to Biopsy: The Role for PSA and Novel Biomarkers” at the International Prostate Cancer Update in Vail, Colorado (January 2016)

Prostate Cancer Foundation: Women in Prostate Cancer Research- Dr Stacy Loeb (published March 17, 2017)

Prostate Cancer Foundation: Women in Prostate Cancer Research- Dr Stacy Loeb (published March 17, 2017

Interview on Katz’s Corner

Interview on Katz’s Corner on 77 WABC Radio about Erectile Dysfunction Medications and Risk of Melanoma (June 28, 2015)

https://audioboom.com/boos/3323526-6-28-15-dr-stacy-loeb-prostate-cancer-supplements

Onc Live Interview on Considerations for Screening in Prostate Cancer (June 2016)

Lecture on the Role of Biomarkers in Prostate Cancer Surveillance

Lecture on the Role of Biomarkers in Prostate Cancer Surveillance for the NYU Cancer Center Community Education Series (October 2015)

MedPage Today Interview on Viagra and Melanoma: Search for Link Inconclusive

6/2015 MedPage Today Interview on Viagra and Melanoma: Search for Link Inconclusive

http://www.medpagetoday.com/Urology/ErectileDysfunction/52272

Urology Times on Twitter in Urology

5/2014 Urology Times on Twitter in Urology

Twitter and Urology- Targeted Oncology Interview

5/2014 Twitter and Urology- Targeted Oncology Interview

Lecture on Social Media in Medicine at International Continence Society in Rio de Janiero

10/2014 Lecture on Social Media in Medicine at International Continence Society in Rio de Janiero

Australia TV appearance video

8/2013 Australia TV appearance video

http://mobile.abc.net.au/news/2013-08-06/new-blood-test-offers-improved-treatment-for/4867150

Arise TV appearance on prostate cancer

6/2014 Arise TV appearance on prostate cancer

ASCO/MedPage Today video on Active Surveillance

5/2015 ASCO/MedPage Today video on Active Surveillance

http://www.medpagetoday.com/ASCOVideoConferenceReporterAUA/special-reports/AUA2015Video-Videos/1143

Seminar on prostate cancer screening at Laura and Isaac Perlmutter NYU Cancer Center

Global Congress on Prostate Cancer Panel Discussion: “Turning the tables: putting the expert in the patient’s seat”

2/2015 Global Congress on Prostate Cancer Panel Discussion: “Turning the tables: putting the expert in the patient’s seat”

http://library.mirrorsmed.org/sessions/turning-tables-putting-expert-patients-seat

Global Congress on Prostate Cancer Lecture on Screening and Early Diagnosis of Prostate Cancer

2/2015 Global Congress on Prostate Cancer Lecture on Screening and Early Diagnosis of Prostate Cancer

http://library.mirrorsmed.org/sessions/screening-and-early-diagnosis-prostate-cancer

Cancer Research and Oncology Virtual Conference: Lecture on Active Surveillance: Trends in Use, Patient Selection & Monitoring

10/2015 Cancer Research and Oncology Virtual Conference: Lecture on Active Surveillance: Trends in Use, Patient Selection & Monitoring September 30, 2015

Lecture topic: Active Surveillance: Trends in Use, Patient Selection and Monitoring

Category: prostate cancer

Location: online

Uro Today Video on Guideline of Guidelines: Prostate Cancer Screening

9/2014 Uro Today Video on Guideline of Guidelines: Prostate Cancer Screening

http://www.urotoday.com/urology-tube/2014-09-18-03-04-51/urology-tube-prostate-cancer/460-guideline-of-guidelines-prostate-cancer-screening.html

Congreso Centroamericano y Del Caribe de Urologia- Highlights of the 2014 AUA

8/2014 Congreso Centroamericano y Del Caribe de Urologia- Highlights of the 2014 AUA

American Urological Association Prostate Cancer Updates Course

5/2014 American Urological Association Prostate Cancer Updates Course

English links:

https://www.auanet.org/university/live-course-video.cfm?id=767&video=478&agenda=3298

https://www.auanet.org/university/live-course-video.cfm?id=767&video=520&agenda=3298

Spanish links:

https://www.auanet.org/university/live-course-video.cfm?id=767&video=521&agenda=3298

https://www.auanet.org/university/live-course-video.cfm?id=767&video=522&agenda=3298

Lecture on Prostate Cancer Screening in USA

Lecture on Prostate Cancer Screening in USA at the Russian Ministry of Health, Institute of Urology in Moscow (Russian translation) (March 2014)

Скрининг РПЖ цели, эффективность, экономическая оценка на примере исследований ERSPC

Lecture on Prostate Cancer Markers at the Russian Ministry of Health

Lecture on Prostate Cancer Markers at the Russian Ministry of Health, Institute of Urology in Moscow (Russian translation) (March 2014)

Место современных биомаркеров в ранней диагностике и динамическом наблюдении пациентов

The Doctor’s Channel video on PSA Screening- Decision Making at the Individual Level

6/2012 The Doctor’s Channel video on PSA Screening- Decision Making at the Individual Level

http://www.thedoctorschannel.com/view/psa-screening-decision-making-at-the-individual-level/collection/prostatecancer/

Australasian Prostate Cancer Conference- Lecture on prostate cancer overdiagnosis and overtreatment

8/2012 Australasian Prostate Cancer Conference- Lecture on prostate cancer overdiagnosis and overtreatment

The Doctor’s Channel video on Prostate Cancer Biopsy Guidelines and Procedures

6/2012 The Doctor’s Channel video on Prostate Cancer Biopsy Guidelines and Procedures

http://www.thedoctorschannel.com/view/prostate-cancer-biopsy-guidelines-and-procedures/collection/prostatecancer/

West Africa

International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19

whatisnew

WALL STREET JOURNAL ARTICLE ON PROSTATE CANCER TESTS

Sirius XM Channel 110 Doctor Radio

Dr. Loeb

Hosts the Men’s Health Show on US/Canada satellite radio Sirius XM channel 110

On Wednesdays from 6-8pm EST.

https://www.siriusxm.com/doctorradio/weeklyschedule

Report: Forbes article about Viagra & Melanoma

EUROPE / MIDDLE EAST

Active

Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System

Loeb S, Byrne NK, Wang B, Makarov DV, Becker D, Wise DR, Lepor H, Walter D.

“Exploring Variation in the Use of Conservative Management for Prostate Cancer in the Veterans Affairs Healthcare System.”

European Urology. 2020 Feb 22:S0302-2838(20)30101-9. PMID: 32098730.

Link: https://pubmed.ncbi.nlm.nih.gov/32098730/

Untitled

Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA.

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Untitled

Loeb S.

“Active Surveillance for Prostate Cancer.”

Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148

Loeb S.

” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

“Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub. PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub. PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.”

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

“A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub. PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.”

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693

Tosoian JJ, Carter HB, Lepor A, Loeb S.

“Active surveillance for prostate cancer: current evidence and contemporary state of practice.”

Nature Reviews Urology 2016 Mar 8 epub. PMID: 26954332.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26954332

Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke PL, Schaeffer EM.

“Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.”

American Society of Clinical Oncology Educational Book. 2016;35:e235-45. PMID: 27249729

Link: http://www.ncbi.nlm.nih.gov/pubmed/26954332

Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P.

“Immediate versus delayed prostatectomy: Nationwide population-based study.”

Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27067998

Loeb S, Curnyn C, Sedlander E.

“Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.”

European Urology 2016 Jun 6 epub. PMID: 27283215.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27283215

Loeb S, Carter HB, Schwartz M, Fagerlin A, Braithwaite RS, Lepor H.

“Heterogeneity in active surveillance protocols worldwide.”

Reviews in Urology 2014;16(4):202-3. PMID: 25548550.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274180/

Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P.

“Five-Year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer.”

Eur Urol 2014, June epub.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24993868

Other Original Papers

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

“Overdiagnosis and Overtreatment of Prostate Cancer.”

European Urology 2014; epub Jan 9. PMID: 24439788

Link: http://www.ncbi.nlm.nih.gov/pubmed/24439788

Other Original Papers

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

“Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer.”

Journal of Urology 2013 epub September 23.

Link: http://www.ncbi.nlm.nih.gov/pubmed/24071481

Key Papers

Loeb S, Berglund A, Stattin P.

“Population-Based Study of Utilization and Determinants of Active Surveillance and Watchful Waiting for Low- and Intermediate-Risk Prostate Cancer”

Journal of Urology 2013 May 29 epub. PMID: 23727309

Link: http://www.ncbi.nlm.nih.gov/pubmed/23727309

Reviews/Editorials

Loeb S.

“Does Delaying Prostate Cancer Treatment Miss the Window of Curability?”

European Urology 2013 epub Apr 8. PMID: 23619388

Link: http://www.ncbi.nlm.nih.gov/pubmed/23619388

Key Papers

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

“Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer.”

Journal of Urology October 2012; 188: 1131-6. PMID: 22901577.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22901577

Key Papers

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC.

“Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.”

Journal of Clinical Oncology, June 2010; 28: 2810.

Link: http://www.ncbi.nlm.nih.gov/pubmed/20439642

Reviews/Editorials

Loeb S and Catalona WJ.

“Counterpoint: the case for active treatment.”

Journal of the National Comprehensive Cancer Network, August 2007; 5: 699.

Link: http://www.ncbi.nlm.nih.gov/pubmed/17692174

Reviews/Editorials

Loeb S and Catalona WJ.

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Untitled

Loeb S.

“Active Surveillance for Prostate Cancer.”

Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

Link: https://www.ncbi.nlm.nih.gov/pubmed/30288148

Loeb S.

” Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer.”

European Urology. 2017 Nov 20. PMID: 29169932

Link: https://www.ncbi.nlm.nih.gov/pubmed/29169932

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

“Informational needs during active surveillance for prostate cancer: A qualitative study.”

Patient Education Counseling 2017 Sep 1 epub. PMID: 28886974

Link: https://www.ncbi.nlm.nih.gov/pubmed/28886974

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

“Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions”.

European Urology 2017 Aug 22 epub. PMID: 28844371

Link: https://www.ncbi.nlm.nih.gov/pubmed/28844371

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28621058

Choyke PL and Loeb S.

“Active Surveillance of Prostate Cancer.”

Oncology (Williston Park) 2017; 31 (1).

PMID 8090626

Link: https://www.ncbi.nlm.nih.gov/pubmed/28090626

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

“A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.”

BJU International. 2016 epub. PMID: 27611479.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27611479

Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P.

“Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden”.

JAMA Oncology. 2016 Oct 20. PMID: 27768168.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27768168

Loeb S. Editorial Comment on

“Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.”

Journal of Urology 2016 epub Nov 28. PMID: 27908693.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27908693

Africa

International Volunteers in Urology

Ghana (Virtual). April 2020

Topic: Virtual Visiting Professor Panel Discussion on COVID-19

Category: COVID-19

World Congress of Endourology 2016

Capetown, South Africa. November 8-12, 2016
Lecture topic: Social media in urology
Category: Social Media

ASIA

Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer

21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation

Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media

2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media

USANZ New Zealand Section

Tauranga, New Zealand . October 11-13, 2017

Lecture Topic: Localized prostate cancer update, active surveillance, prostate cancer markers, social media

Category: prostate cancer, social media

Astellas Prostate Cancer Meeting

Hobart, Australia. April 8, 2017

Lecture topic: Markers and Prostate Cancer Screening

Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Melbourne, Australia. April 7, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Australian Prostate Cancer Conference

Melbourne, Australia. August 2012

Lecture Topics: Prostate biopsy complications, Overdiagnosis and Overtreatment of Prostate Cancer

Category: Prostate Complications

Australia

21st Asia-Pacific Prostate Cancer Conference

Australia (Virtual). October 2020

Topic: Key Papers in Detection and Localized Prostate Cancer, Women in Urology and Leveraging Social Media

Category: Prostate Cancer, Social Media, Representation

Clinical Oncology Society of Australia

Adelaide, Australia – November 12-14, 2019

Lecture topics: Latest developments in prostate cancer surgery and active surveillance; Promise and peril of social media for clinicians, researchers and patients

Category: Prostate Cancer Treatment, Active Surveillance, Social Media

2018 Prostate Cancer World Congress

Brisbane Australia . August 22-246, 2018

Lecture Topic: Active surveillance for prostate cancer, Social media in prostate cancer

Category: Prostate Cancer, Social Media

USANZ New Zealand Section

Tauranga, New Zealand . October 11-13, 2017

Lecture Topic: Localized prostate cancer update, active surveillance, prostate cancer markers, social media

Category: prostate cancer, social media

Astellas Prostate Cancer Meeting

Hobart, Australia. April 8, 2017

Lecture topic: Markers and Prostate Cancer Screening

Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Melbourne, Australia. April 7, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Sydney, Australia. April 5-6, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Adelaide, Australia. April 4, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Astellas Prostate Cancer Meeting

Brisbane, Australia. April 3, 2017
Topic: Markers and Prostate Cancer Screening
Category: Prostate Cancer

Macquarie University Markers Symposium

Sidney, Australia. September 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer, Markers

Prostate Cancer World Congress

Cairns, Australia. August 2015

Lecture Topics: Key publications in prostate cancer, Active Surveillance for prostate cancer, Updates to Gleason grading, Social Media and Prostate Cancer.

Category: Prostate Cancer

Prostate Cancer World Congress

Melbourne, Australia. August 2013

Category: Prostate Cancer

Australian Prostate Cancer Conference

Melbourne, Australia. August 2012

Lecture Topics: Prostate biopsy complications, Overdiagnosis and Overtreatment of Prostate Cancer

Category: Prostate Complications

Benign Disease

BenignDisease

An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“An Evaluation of the Readability and Content-Quality of Pelvic Organ Prolapse YouTube Transcripts.”

Urology 2021; S0090-4295(21)00266-1. PMID: 33775787.

Link: https://pubmed.ncbi.nlm.nih.gov/33775787/

Fake News about Benign Prostate Hyperplasia on YouTube

Loeb S.

“Fake News about Benign Prostate Hyperplasia on YouTube.”

British Journal of Urology International. 2020 Apr;125(4):477-478. PMID: 32250050

Link: https://pubmed.ncbi.nlm.nih.gov/32250050/

Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information

Herbert AS, Nemirovsky A, Hess DS, Walter D, Abraham NE, Loeb S, Malik RD.

“Pelvic Organ Prolapse on YouTube: Evaluation of Consumer Information.”

British Journal of Urology International 2020 Feb 10 epub. PMID: 32039554.

Link: https://pubmed.ncbi.nlm.nih.gov/32039554/

Key Paper

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.

Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ.

“Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.”

Journal of Uroloy 2012 epub November. PMID: 23159463.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159463

Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.

Loeb S, Semins MJ, and Matlaga BR.

“Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.”

Urology, August 2012; 80: 474. PMID: 22857764.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22857764

Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis.

Gupta AD, Loeb S, Stec A, and Wang MH.

“Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis.”

Urology December 2011; 78: 1414-6. PMID: 21676451.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21676451

Prestenting Improves Ureteroscopic Stone-Free Rates.

Rubenstein RA, Zhao LC, Loeb S, Shore DM, and Nadler RB.

“Prestenting Improves Ureteroscopic Stone-Free Rates.”

J Endourol, November 2007; 21: 1277.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18042014

Contemporary Management of Urosepsis: Updated Critical Care Guidelines.

Loeb S, Vardi IY, and Nadler RB.

“Contemporary Management of Urosepsis: Updated Critical Care Guidelines.”

Contemporary Urology, July 2005

Biomarkers

Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer

Wysock JS, Becher E, Persily J, Loeb S, Lepor H.

“Concordance and Performance of 4KScore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer.”

Urology. 2020 Apr 12:S0090-4295(20)30339-3. PMID: 32294481

Link: https://pubmed.ncbi.nlm.nih.gov/32294481/

Untitled

Fine ND, LaPolla F, Epstein M, Loeb S, Dani H.

” Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer.”

BJU International 2019 May epub. PMID:31055874.

Link: https://www.ncbi.nlm.nih.gov/pubmed/31055874

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance. “

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029c

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869

Loeb S, Dani H.

“Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268

Dani H, Loeb S.

“The Role of Prostate Cancer Biomarkers in Undiagnosed Men.”

Current Opinion Urology 2017; 27: 210-216. PMID 28212119

Link: https://www.ncbi.nlm.nih.gov/pubmed/28212119

Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28661898

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489

Lepor A, Catalona WJ, Loeb S.

“The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics North America.”

2016 Feb;43(1):1-6. PMID: 26614024

Link: http://www.ncbi.nlm.nih.gov/pubmed/26614024

Loeb S.

“Prostate Cancer: Is PSA Velocity Useful?”

Nature Reviews Urology, June 2009; 6: 305.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19498408

BJU International. 2018 May 22. PMID: 29786946

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029c

Loeb S, Tosoian JJ.

“Biomarkers in Active Surveillance.”

Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29594029

Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL.

” A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men.”

Journal of Urology 2017, epub Dec 6. PMID: 29223389

Link: https://www.ncbi.nlm.nih.gov/pubmed/29223389

” Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.”

Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869.

Link: https://www.ncbi.nlm.nih.gov/pubmed/29185869

Loeb S, Dani H.

“Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.”

Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

Link: https://www.ncbi.nlm.nih.gov/pubmed/29107268

Dani H, Loeb S.

“The Role of Prostate Cancer Biomarkers in Undiagnosed Men.”

Current Opinion Urology 2017; 27: 210-216. PMID 28212119

Link: https://www.ncbi.nlm.nih.gov/pubmed/28212119

Loeb S.

“Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.”

Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

Link: https://www.ncbi.nlm.nih.gov/pubmed/29104903

Loeb S, Ross AE.

“Genomic testing for localized prostate cancer: where do we go from here?”

Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

Link: https://www.ncbi.nlm.nih.gov/pubmed/28661898

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ.

“Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer”

BJU International. 2016 Oct 15. PMID:27743489

Link: https://www.ncbi.nlm.nih.gov/pubmed/27743489

Lepor A, Catalona WJ, Loeb S.

“The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics North America.”

2016 Feb;43(1):1-6. PMID: 26614024

Link: http://www.ncbi.nlm.nih.gov/pubmed/26614024

Loeb S.

“Prostate Cancer: Is PSA Velocity Useful?”

Nature Reviews Urology, June 2009; 6: 305.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19498408

Loeb S and Catalona WJ.

“Cancer Biomarkers: Discovery and Validation.”

Cancer Letters, January 2007

Key Papers

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ.

“The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer.”

Journal of Urology 2014 Nov 15 epub. PMID:25463993

Link: http://www.ncbi.nlm.nih.gov/pubmed/25463993

Key Papers

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

“Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.”

BJU International. 2012 Feb;109(4):508-13. PMID: 22296334

Link: http://www.ncbi.nlm.nih.gov/pubmed/22296334

Key Papers

Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA.

Journal of Urology May 2011; 185: 1650. PMID: 21419439.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21419439

Blog

Urology Care Foundation- A Great Source of Patient Information

Welcome to Dr. Stacy Loeb’s blog!

Welcome to Dr. Stacy Loeb’s blog! Stay tuned to this section for urology updates, research findings and conference highlights. Check the publications tab for previous research related to:

prostate cancer: PSA Screening, biomarkers, genetics, epidemiology, prostate biopsy, staging, active surveillance, treatment.
other urology topics: surgical technique, uro-oncology, benign disease
social media

Brazil

Paulista Congress of Urology

Brazil (Virtual). October 2020

Topic: Prostate Cancer Screening, Markers and Genetic Testing

Category: Prostate Cancer, Genetics

International Continence Society

Rio de Janiero, Brazil. October 2014

Lecture Topic: Social Media in Medicine

Category: Social media

Canada

Société Internationale d’Urologie

Montreal (Virtual). April 2020

Topic: Webinar on Economic and Financial Burden of COVID-19

Category: COVID-19

Queens University Visiting Professor

Kingston, Ontario – October 18-19, 2018

Lecture Topics: Social Media in Men’s Health (6th Annual Alvaro and Diane Morales Public Lecture in Men’s Health); Active Surveillance for Prostate Cancer.

Category: Men’s Health, Social Media, Prostate Cancer, Active Surveillance

Canadian Urological Association 2017 Meeting

Toronto, Canada- June 24-27, 2017

Lecture topics: Optimizing Active Surveillance for Prostate Cancer, Serum and Urine Markers to Select Patient for Initial and Repeat Prostate Biopsy

Category: Prostate cancer

Issues & Controversies in Urologic Cancer (ICUC) Conference 2017

Mony Tremblant, Canada. January 19-21, 2017

Lecture Topics: Prostate Cancer Markers, Active Surveillance, Prostate Biopsy

Category: Prostate Cancer

The 10th Atlantic Uro Oncology Meeting

Halifax, Canada. November 14, 2015

Lecture Topics: Prostate Cancer Markers and Active Surveillance

Category: Prostate Cancer

Visiting professor at University of Toronto

Toronto, Canada. October 2014

Lecture Topics: Prostate Biopsy, Active Surveillance

Category: Prostate Cancer

Colombia

1ER CURSO BIENAL DE INNOVACÍON UROLÓGICA SOCIEDAD COLOMBIANA DE UROLOGÍA

Barranquilla, Colombia. October 2015

Lecture Topics (all in Spanish): Prostate -specific Antigen and Biomarkers, Prevention and Management of Prostate Biopsy Complications, Active Surveillance

Category: Prostate Cancer

Second Update Course in Urology (Curso de Actualización en Urología)

Barranquilla, Colombia. March 2015

Lecture Topics: Prostate cancer screening, prostate cancer markers, prostate biopsy

Category: Prostate Cancer

Visiting Professor at Fundación Santa Fe de Bogotá Fundación

Barranquilla, Colombia. March 2015

Lecture Topics: Prostate Cancer Screening, Serum and Urine Markers for Prostate Cancer, Contemporary Prostate Biopsy, Active Surveillance, Social Media in Urology

Categories: Prostate Cancer, Social Media

Sociedad Colombiana de Urologia

Cartagena, Colombia. March 2014

Lectures Topics: PSA screening, Risks of Prostate Biopsy, Active Surveillance, Prostate MRI-based Detection, Castration Resistant Prostate Cancer, and Twitter in Urology

Categories: Prostate Cancer, Social Media

Colorado - USA

Conference Highlights

ConferenceHighlights

Nickel JC, Gorin MA, Alan W P, Loeb S, Ellen S, Chancellor MB, Assimos DG, Brawer MK, Brucker BM.

“Best of the 2016 AUA Annual Meeting: Highlights From the 2016 American Urological Association Annual Meeting, May 6-10, 2016, San Diego, CA.”

Reviews in Urology 2016;18(3):159-173. PMID: 27833468.

Link: https://www.ncbi.nlm.nih.gov/pubmed/27833468

Nickel JC, Gorin MA, Partin AW, Assimos D, Brawer M, Nicolai H, Chancellor MB, Goggins Á, Loeb S, Shapiro E.

“Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.”

Reviews in Urology 2015;17(3):179-89. PMID: 26543434

Link: http://www.ncbi.nlm.nih.gov/pubmed/26543434

Prostate Cancer Screening Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014.

Loeb S.

“Prostate Cancer Screening Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014.”

Reviews in Urology 2014; 16: 90. PMID: 25009450.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080855/

Advances in Localized Prostate Cancer: Highlights From the 2012 Friends of Israel Urological Symposium, July 3-5, 2012, Tel Aviv, Israel.

Loeb S, Borin JF.

“Advances in Localized Prostate Cancer: Highlights From the 2012 Friends of Israel Urological Symposium, July 3-5, 2012, Tel Aviv, Israel.”

Reviews in Urology 2013; 15: 82.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784972/

Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA.

Loeb S, Assimos D, Chancellor MB, Nickel JC, Brawer MK, Kern AJ, Partin AW.

“Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA..”

Reviews in Urology 2013; 15: 72.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784971/

Best of 2012 AUA Annual Meeting: Highlights from the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.

Nickel JC, Partin AW, Nirmal J, Chancellor MB, Loeb S, Brawer MK, Assimos D, and Shapiro E.

“Best of 2012 AUA Annual Meeting: Highlights from the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.”

Reviews in Urology 2012; 14: 90-103. PMID: 23526762

Link: http://www.ncbi.nlm.nih.gov/pubmed/23526762

Prostate Cancer Screening and Surgical Management of Localized Disease: Highlights from the 27th Annual Congress of the European Association of Urology, February 24-28, 2012, Paris, France.

Loeb S.

Reviews in Urology 2012; 14: 87-9. PMID: 23526727

Link: http://www.ncbi.nlm.nih.gov/pubmed/23526727

Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.

Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A.

“Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.”

BJU International 2012; 109 Suppl 2: 1-7. PMID: 22257098.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22257098

Best of the AUA Annual Meeting: Highlights from the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.

Brawer MK, Loeb S, Partin AW, Nirmal J, Chancellor MB, Nickel JC, Rajfer J, Shapiro E, and Roehrborn CG.

“Best of the AUA Annual Meeting: Highlights from the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.”

Reviews in Urology 2011; 13: 151-72. PMID: 22114546.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725309/

Innovation in Endourology and Minimally Invasive Surgery. Highlights from the 29th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan.

Loeb S and Borin JF.

“Innovation in Endourology and Minimally Invasive Surgery. Highlights from the 29^th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan.”

Reviews in Urology 2012; 14: 28-30. PMID: 23172997.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502049/

Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.

Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, and Shapiro E.

“Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.”

Reviews in Urology, Spring 2009; 11: 82.

Costa Rica

Congreso Centroamericano y del Caribe de Urología y II Highlights of the 2014 American Urological Association Meeting

San Jose, Costa Rica. August 2014

Lectures on: Active surveillance for prostate cancer, Highlights of the AUA meeting on Localized Prostate Cancer

Category: Prostate Cancer

Covid19

Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study

Dubin JM, Wyant WA, Balaji NC, Ong WL, Kettache RH, Haffaf M, Zouari S, Santillan D, Autrán Gómez AM, Sadeghi-Nejad H, Loeb S, Borin JF, Gomez Rivas J, Grummet J, Ramasamy R, Teoh JYC.

“Telemedicine Usage Among Urologists During the COVID-19 Pandemic: Cross-Sectional Study.”

J Med Internet Res. 2020 Nov 5;22(11):e21875. PMID: 33031047.

Link: https://pubmed.ncbi.nlm.nih.gov/33031047/

The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future

Wallis CJD, Catto JWF, Finelli A, Glaser AW, Gore JL, Loeb S, Morgan TM, Morgans AK, Mottet N, Neal R, O’Brien T, Odisho AY, Powles T, Skolarus TA, Smith AB, Szabados B, Klaassen Z, Spratt DE.

“The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.”

Eur Urol. 2020 Nov;78(5):731-742. PMID: 32893062.

Link: https://pubmed.ncbi.nlm.nih.gov/32893062/

Urologic Services in Public Hospitals Suffered a Greater Detriment Than Private Hospitals During the Battle of COVID-19

Ong WLK, Lechmiannandan S, Loeb S, Teoh JY.

“Urologic Services in Public Hospitals Suffered a Greater Detriment Than Private Hospitals During the Battle of COVID-19.”

Urology. 2020 Oct; 144:269-270. Epub 2020 Jul 18.PMID: 32687841.

Link: https://pubmed.ncbi.nlm.nih.gov/32687841/

Telemedicine and Smart Working: Recommendations of the European Association of Urology

Rodriguez Socarrás M, Loeb S, Teoh JY, Ribal MJ, Bloemberg J, Catto J, N’Dow J, Van Poppel H, Gómez Rivas J.

“Telemedicine and Smart Working: Recommendations of the European Association of Urology”

Eur Urol. 2020 Dec;78(6):812-819. PMID: 32654801.

Link: https://pubmed.ncbi.nlm.nih.gov/32654801/

A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic

Heldwein FL, Loeb S, Wroclawski ML, Sridhar AN, Carneiro A, Lima FS, Teoh JY.

“A Systematic Review on Guidelines and Recommendations for Urology Standard of Care During the COVID-19 Pandemic.”

Eur Urol Focus. 2020 Jun 5 epub. PMID: 32532703.

Link: https://pubmed.ncbi.nlm.nih.gov/32532703/

A Global Survey on the Impact of COVID-19 on Urological Services

“A Global Survey on the Impact of COVID-19 on Urological Services.”

Eur Urol. 2020 May 26 epub. PMID: 32507625.

Link: https://pubmed.ncbi.nlm.nih.gov/32507625/

Dominican Republic

Sociedad Dominicana de Urologia

Punta Cana, Dominican Republic. November 2013

Lectures Topics: PSA Screening, Prostate Cancer Markers, and Prostate Biopsy Complications

Category: Prostate Cancer

Drugsafety

Key Papers

drug safety

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

The relationship between testosterone replacement therapy and prostate cancer risk is controversial. We found no association between testosterone therapy and overall prostate cancer risk. Long-term testosterone therapy was associated with a significantly reduced risk of aggressive prostate cancer.

Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P.

“Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.”
European Urology. 2015 Dec 29 epub. PMID: 26743040

Link: http://www.ncbi.nlm.nih.gov/pubmed/26743040

A previous study from Germany reported a significantly increased risk of prostate cancer recurrence in men taking phosphodiesterase type 5 (PDE5) inhibitors after radical prostatectomy, which was subsequently refuted in an Italian study. We followed up on this issue using nationwide Swedish registry data, and confirmed that there is no association between PDE5 inhibitors with prostate cancer recurrence after treatment.

Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P.

“Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.”

JAMA 2015; 313: 2449-55. PMID: 26103029.

Link: http://www.ncbi.nlm.nih.gov/pubmed/26103029

A recent study suggested a possible link between phosphodiesterase inhibitors used for erectile dysfunction and risk of malignant melanoma. Through a large collaboration with the national registries of Sweden, we performed a large study that raised questions about a causal relationship including lack of a dose-response relationship. Instead, the observed association between erectile dysfunction drugs and melanoma likely reflects shared risk factors including lifestyle and socioeconomic status.

Other Papers

Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P.

“Opiod. Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden”

J Urol. 2019 Jul 17 epub. PMID:31584849

Link: https://www.ncbi.nlm.nih.gov/pubmed/31584849

Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P.

“Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.”

J Natl Cancer Inst. 2017 Aug 1;109(8). PMID: 29117385

Link: https://www.ncbi.nlm.nih.gov/pubmed/29117385

Loeb S, Stattin P.

“Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma.”

European Urology 2016 Jul 16 epub. PMID: 27436160.

Link: http://www.ncbi.nlm.nih.gov/pubmed/27436160

Loeb S, Lambe M, Stattin P.

“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

Loeb S, Lambe M, Stattin P.
“Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.”

Journal of Urology 2016 epub. PMID: 26783933

Link: http://www.ncbi.nlm.nih.gov/pubmed/26783933

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Loeb S.

“Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.”

Urology August 2011; 78: 255. PMID: 21820566.

England

Royal Society of Medicine

UK (Virtual). June 2020

Topic: COVID-19 and Active Surveillance

Category: Prostate Cancer, COVID-19

European Association of Urology 2017 Congress

London, England. 2017

Lecture topic: Social Media

Category: Social Media

Royal Society of Medicine Urology Section Prostate Cancer Conference

London, England. Ocrober 21, 2016

Lecture topic: Active Surveillance- USA Perspective

Category: Prostate Cancer

Epidemiology

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

Reviews/Editorials

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159990

Mullins JK, Loeb S.

“Environmental exposures and prostate cancer.”

Urologic Oncology: Seminars and Investigations, March 2012; 30: 216. PMID: 22385992.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22385992

REVIEWS/EDITORIALS

Mullins JK and Loeb S.

“Diabetes Mellitus and Prostate Cancer Risk.”

Expert Review of Endocrinology and Metabolism November 2010; 5: 787.

Reviews/Editorials

Loeb S and Partin AW.

“Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention.”

Reviews in Urology, Spring 2009; 11: 114.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725311/

Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

Primary Care Clinics of North America, September 2009; 36: 603.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19616157

Epidemiology

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/

Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA

“Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?”

Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25342390

Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P.

“Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.”

Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

Link: https://www.ncbi.nlm.nih.gov/pubmed/28447913

Reviews/Editorials

Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC.

“Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?”

Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

Link: http://www.ncbi.nlm.nih.gov/pubmed/23159990

Mullins JK, Loeb S.

“Environmental exposures and prostate cancer.”

Urologic Oncology: Seminars and Investigations, March 2012; 30: 216. PMID: 22385992.

Link: http://www.ncbi.nlm.nih.gov/pubmed/22385992

REVIEWS/EDITORIALS

Mullins JK and Loeb S.

“Diabetes Mellitus and Prostate Cancer Risk.”

Expert Review of Endocrinology and Metabolism November 2010; 5: 787.

Reviews/Editorials

Loeb S and Partin AW.

“Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention.”

Reviews in Urology, Spring 2009; 11: 114.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725311/

Loeb S and Schaeffer EM.

“Risk Factors, Prevention, and Early Detection of Prostate Cancer.”

WALL STREET JOURNAL ARTICLE ON PROSTATE CANCER TESTS

Genetics

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/

Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Loeb S. and Giri VN.

“Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.”

Eur Urol Oncol. 2021 Feb;4(1):1-9. Epub 2020 Dec 31. PMID: 33390340

Link: https://pubmed.ncbi.nlm.nih.gov/33390340/

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.

Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.

“Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.”

Cancer Treat Res Commun. 2020 Sep 28;25:100212. PMID: 33091732

Link: https://pubmed.ncbi.nlm.nih.gov/33091732/

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379

Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622

Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897

Key Papers

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

Reviews/Editorials

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739

Genetics

Prostate Cancer. Nature Reviews Disease Primers

Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG.

“Prostate Cancer. Nature Reviews Disease Primers.”

2021 Feb 4;7(1):9. PMID: 33542230.

Link: https://pubmed.ncbi.nlm.nih.gov/33542230/

Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer

Loeb S. and Giri VN.

“Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.”

Eur Urol Oncol. 2021 Feb;4(1):1-9. Epub 2020 Dec 31. PMID: 33390340

Link: https://pubmed.ncbi.nlm.nih.gov/33390340/

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

“Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.”

Journal of Clinical Oncology 2020 Jun 9 epub. PMID: 32516092.

Link: https://pubmed.ncbi.nlm.nih.gov/32516092/

Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.

Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.

“Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.”

Cancer Treat Res Commun. 2020 Sep 28;25:100212. PMID: 33091732

Link: https://pubmed.ncbi.nlm.nih.gov/33091732/

Loeb S, Braithwaite RS, Hayes RB.

“Utility of single nucleotide polymorphisms in prostate biopsy decisions.”

Reviews in Urology 2012; 14: 115-7.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602735/

Loeb S. Editorial Comment on

“Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.”

Urology 2015; 85: 170. PMID: 25530380.

Link: http://www.ncbi.nlm.nih.gov/pubmed/25530379

Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D’Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

Link: http://www.ncbi.nlm.nih.gov/pubmed/21411622

Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ.

“Pathological Outcomes Associated with the 17q Prostate Cancer Risk Variants.”

Journal of Urology, June 2009; 181: 2502.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19371897

Key Papers

Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ.

“Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.”

Journal of Urology, July 2009; 182: 101.

Link: http://www.ncbi.nlm.nih.gov/pubmed/19450841

Genotype influences the risk of prostate cancer per unit increase in PSA. Prostate cancer risk stratification using PSA and genotype together could improve PSA test performance.

Reviews/Editorials

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

Loeb S and Partin AW.

“Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.”

Reviews in Urology, Fall 2008; 10: 304.

Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615108/

Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ.

“Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.”

Journal of Urology, June 2008; 179: 2197.

Link: http://www.ncbi.nlm.nih.gov/pubmed/18423739

Germany

Association of Academic European Urologists (AAEU)

Dresden, Germany . December 15-16, 2017

Lecture Topic: Active surveillance for prostate cancer

Category: Prostate Cancer

Heinrich Warner Symposium

Hamburgo, Germany. June 23-24, 2017

Lecture Topic: Clinical Use of Markers in Localized Prostate Cancer

Category: Prostate Cancer

European Association of Urology

Munich, Germany. March 11-14, 2016

Lecture Topics: Prostate Cancer Markers

Category: Prostate Cancer

Heinrich Warner Symposium

Hamburg, Germany. January 2015

Lecture Topics : Genomic and Epigenetic Variations in Prostate Cancer

Category: Prostate Cancer

Grants Completed

Grants Current

Hong Kong

Chinese University of Hong Kong Urology Symposium

Hong Kong (Virtual). November 2020

Topic: Prostate Cancer Screening: Evidence, Guidelines and Implementation; Updates on Prostate Cancer in 2019-2020

Category: Prostate Cancer

Hungary

International Genitourinary Cancer Symposium (IGUCC 3)

Budapest, Hungary. March 2011

Lecture Topics: Debate on Active Surveillance, Panel on Controversies in Prostate Cancer

Category: Prostate Cancer

Ireland

John Fitzpatrick Irish Prostate Cancer Conference

Ireland. April 21-22, 2016

Surgery in the 3rd Millennium: The Future is Female

Milan, Italy – April 4-5, 2019

Lecture Topics: When not to do surgery: expanding active surveillance for low-risk prostate cancer; Moderation for Retzius-Sparing Robotic Prostatectomy

Category: Prostate Cancer, Active Surveillance, Surgical Technique

Association of Academic European Urologists (AAEU) Meeting

Rome, Italy . November 30, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer

State-of-the-Art Lecture, Association of Academic European Urologists

Roma, Italy .November, 2018

Lecture Topic: Prostate Cancer Journal Club #ProstateJC on Twitter

Category: Social Media, Prostate Cancer

iTRUST International Translational Research Uro-Sciences Team

Roma, Italy .September 26-27, 2018

Lecture Topic: Social Media & Cancer Care: Where are we going?

Category: Cancer, Social Media

Global Congress on Prostate Cancer (PROSCA)

Rome, Italy. February 2015

Lecture topic: PSA Screening Yes or No

Category: Prostate Cancer